Body Weight

The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Synonym
Body Weight

Synonym

Body Weight

Research Excerpts

Overview

Excerpt	Reference
"High body weight is associated with increased production of oestrogens which may influence the clinical behaviour of breast cancer."	( Howell, A; Jones, M; Williams, G, 1988)
"Body weight is reduced in all treated rats (except the low dose of CA) by day 17 of gestation, with greater weight reductions occurring in rats receiving the higher dose level of each steroid."	( Brundage, M; Dearden, LC; Jansons, R; Mosier, HD; Thai, C, 1986)
"The deficits in body weight are explained, in part, by decreased intake of the semipurified diet, most likely attributable to its high sucrose content."	( Greene, FE; Griffith, JW; Halperin-Walega, ES; Shively, CA, 1985)
"Fat-free body weight is usually calculated by difference and serves as a reference for some physiological functions."	( Buskirk, ER; Mendez, J, 1984)
"Because body weight is a highly integrated physiological variable, it is postulated that various diets which affect survivorship would affect body weight frequency distribution similarly."	( Economos, AC; Miquel, J, 1980)
"The increase in body weight is reduced in the animals treated."	( Bien, E; Buntrock, P; Neubauer, J; Skorka, G, 1981)
"Ferring) per kg body weight are given intramuscularly."	( Hofmann-Ehrhart, B; Kluge, M; Schulz, U; Waldhauser, F; Wandl-Vergesslich, K, 1995)
"Excess body weight is associated with deleterious changes in the lipoprotein profile."	( Denke, MA; Grundy, SM; Sempos, CT, 1993)
"Body weight is closely related to several known cardiovascular risk factors, but it may also have an independent effect on the risk of coronary heart disease (CHD)."	( Jousilahti, P; Pekkanen, J; Puska, P; Tuomilehto, J; Vartiainen, E, 1996)
"Food intake and body weight are determined by a complex interaction of regulatory pathways."	( Al-Haider, W; Beinborn, M; Bonner-Weir, S; Kanarek, R; Kopin, AS; Mathes, WF; McBride, EW; Nguyen, M; Schmitz, F, 1999)
"Since the body weight is known to influence leptin concentrations, the hormone was measured in rats with a very similar body weight (about 250 g) throughout this study."	( Suda, T; Watanobe, H, 1999)
"Age and total body weight are important factors influencing digoxin clearance in children."	( Higuchi, S; Minemoto, M; Suematsu, F; Yukawa, E, 1999)
"Body weight is an important attribute of any animal and influences its biology in many ways."	( Müller, AE, 1999)
"Reducing body weight is one of the effective measures to prevent and treat gout or hyperuricemia in the elderly."	( Tang, D; Xia, B, 1998)
"Elevated body weight is a risk factor for postmenopausal breast cancer and is associated with increased incidence of spontaneous and chemically induced mammary tumors (MTs) in rodents."	( Christensen, TA; Cleary, MP; Getzin, SC; Grande, JP; Jacobson, MK; Jacobson, TL; Juneja, SC; Maihle, NJ; Phillips, FC, 2003)
"Body weight is a good indicator of a person's size and is widely used in clinical assessment."	( Mozumdar, A; Roy, SK, 2004)
"Changes in body weight are the result of changes in energy intake, energy expenditure, or both."	( Bray, GA; De Jonge, L; Li, Y; Smith, SR; Volaufova, J; Xie, H, 2005)
"The body weight is therefore a very sensitive parameter in the surveillance and management of Trypanosome infections especially in Yankasa ewes as experimental animal models."	( Adenowo, TK; Njoku, CO; Oyedipe, EO; Sannusi, A, 2004)
"Body weight is a significant predictor of bone mass."	( Baek, KH; Choi, MG; Ihm, SH; Kang, MI; Lee, WY; Oh, KW; Park, CY; Park, SW; Rhee, EJ; Yoo, HJ; Yoon, KH; Yun, EJ, 2005)
"The body weight is driven by a decrease in food intake with the magnitude of the loss of body weight being directly related to the length of time of exposure to short photoperiod."	( Barrett, P; Mercer, JG; Morgan, PJ; Ross, AW, 2006)
"In conclusions, body weight is the primary covariate factor in pediatric patients."	( Kaibara, A; Katashima, M; Kawamura, A; Tabata, K; Tanigawara, Y, 2006)
"Body weight is the only demographic factor that could be related to lopinavir exposure; clinicians should be alert for an increased risk of suboptimal antiviral efficacy in patients with high body weight, and for an increased risk of toxicity in patients with a low body weight."	( Burger, DM; Koopmans, PP; la Porte, CJ; van der Leur, MR, 2006)
"Preoperative body weight is a reliable predictor of post-RYGBP weight loss."	( Czupryniak, L; Kumor, A; Loba, J; Pawlowski, M; Strzelczyk, J; Szymanski, D, 2007)
"The reduction in body weight is sustained following dosing for 40 days, and it is accompanied by an increase in plasma adiponectin."	( Buckholz, TM; Claus, TH; DeCarr, LB; Livingston, JN; Lumb, KJ; Mahle, CD; Mays, MR; Milardo, LF; Ortiz, AA, 2007)
"Body weight is tightly regulated by a feedback mechanism involving peripheral adiposity signals and multiple central nervous system neurotransmitter pathways."	( Benoit, SC; Clegg, DJ; Reizes, O, 2008)
"The regulation of body weight is carried out by the central nervous system in a complex and redundant way, characterized by interconnections and overlaps with other neuroendocrine functions, such as growth, thyroid and adrenal function, memory, addictive and reward mechanisms."	( Csongrádi, E; Juhász, A; Katona, E; Paragh, G, 2007)
"Loss of body weight is associated with bone loss, and body weight gain is associated with increased bone formation."	( Ferrari, SL; Hamrick, MW, 2008)
"The development of body weight is determined by different factors, namely genetic, behavioral, parental and physiological."	( Bouwman, F; Mariman, E; Nieuwenhuizen, AG; Rutters, F; Vogels, N; Westerterp-Plantenga, MS, 2008)
"Body weight is positively correlated with bone mass and density, and both muscle mass and body fat are thought to play a role in regulating bone metabolism."	( Ding, KH; Ferrari, SL; Hamrick, MW; Isales, CM; Ponnala, S, 2008)
"Body weight is regulated by complex neurohormonal interactions between endocrine signals of long-term adiposity (e."	( Anderson, CM; Baron, AD; Cole, RL; Koda, JE; Parkes, DG; Roland, BL; Roth, JD; Trevaskis, JL; Weyer, C, 2008)
"Regulation of body weight is closely linked to the mass and function of individual body components."	( Bosy-Westphal, A; Haas, V; Heller, M; Later, W; Müller, MJ, 2009)
"Body weight is an important risk factor for thromboses and is used in algorithms to determine dosages in prophylaxis."	( Grohs, JG; Lunzer, A; Vavken, P, 2009)
"Body weight is tightly controlled in a species-specific range from insects to vertebrates and organisms have developed a complex regulatory network in order to avoid either excessive weight gain or chronic weight loss."	( Brüning, JC; Könner, AC; Sánchez-Lasheras, C, 2010)
"The heritability of body weight is high, and genetic variation plays a major role in determining the interindividual differences in susceptibility or resistance to the obesogenic environment."	( Farooqi, IS; Ramachandrappa, S, 2011)
"Body weight is found the most closely related factor to the insulin dosage."	( Dong, JJ; Liao, L; Mou, YR; Qiu, LL; Yang, M; Zhao, JJ, 2010)
"Food intake and body weight are controlled by a variety of central and peripheral factors, but the exact mechanisms behind these processes are still not fully understood."	( Breit, SN; Brown, DA; Herzog, H; Johnen, H; Kuffner, T; Lin, S; Macia, L; Nguyen, AD; Sainsbury, A; Shi, YC; Tsai, VW, 2012)
"Body weight is determined by the balance between energy intake and energy expenditure."	( Cotter, PD; Korpela, R; McAllan, L; Nilaweera, KN; Roche, HM, 2013)
"The body weight is closely dependent on the thyroid status and its maintenance seems to involve thyroid action on mechanisms other than feeding and metabolic rate."	( Alva-Sánchez, C; Fregoso-Aguilar, T; Pacheco-Rosado, J; Villanueva, I, 2012)
"Body weight is a predictor of clopidogrel response."	( Angiolillo, DJ; Bergmeijer, TO; Brown, P; Erlinge, D; Jakubowski, JA; James, S; Moser, BA; Small, DS; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C, 2014)
"When total body weight is used, low BMI tended to be associated with amikacin underdosing."	( Bouadma, L; Chemam, S; de Montmollin, E; Gault, N; Mariotte, E; Massias, L; Mourvillier, B; Papy, E; Sonneville, R; Tubach, F; Wolff, M, 2014)
"Both glucose and body weight are regulated by the brain, which contains GLP1 receptors (GLP1R)."	( D'Alessio, DA; Gutierrez-Aguilar, R; Sandoval, DA; Scott, M; Seeley, RJ; Sisley, S, 2014)
"Body weight is a highly heritable trait across species."	( Farooqi, S, 2014)
"Body weight is a better predictor of anti-Xa levels compared to lean body weight."	( Brandjes, DP; Celik, F; Gerdes, VE; Hooijberg, JH; Huitema, AD; van de Laar, AW, 2015)
"Division by total body weight is the usual way to standardise peak oxygen uptake (peak VO2) for body size."	( Hassinen, M; Komulainen, P; Krachler, B; Lakka, TA; Rauramaa, R; Savonen, K, 2015)
"Body weight is determined via both metabolic and hedonic mechanisms."	( Korner, J; Mechanick, JI; Peterli, R; Vasselli, JR; Yu, YH; Zhang, Y, 2015)
"Body weight is perhaps not as well known as a variable affecting VKA dose."	( Sakaan, S; Sands, CW; Self, TH; Wallace, JL, 2015)
"Body weight is maintained via a complex integration of endocrine and neuronal inputs that regulate the control of orexigenic and anorexigenic neuropeptides in the arcuate nucleus of the hypothalamus."	( Benite-Ribeiro, SA; Putt, DA; Santos, JM; Soares-Filho, MC, 2016)
"Body weight is the strongest predictor of procedural heparin requirement during left atrial ablation in patients on uninterrupted rivaroxaban, even in those with an elevated INR."	( Barbhaiya, CR; Chinitz, JS; Churchill, T; Enriquez, AD; Gautam, S; John, RM; Koplan, BA; Kumar, S; Michaud, GF; Stevenson, WG; Tedrow, UB, 2017)
"Body weight is highly associated with overall health status."	( Abdul Manan, NS; Ahmad, A; Ahmed, A; Mohd Amin, R; Shahril, MR; Syed Abdullah, EF; Syed Saadun Tarek Wafa, SW; Zulaily, N, 2017)
"Renal function and body weight are important when considering the need for alternative dosing regimens."	( Ikeda, K; Lipman, J; Naik, BI; Roberts, JA; Roger, C; Todorovic, MS; Wallis, SC, 2017)
"When differences in body weight are corrected for in the appropriate circumstances, we found that males consume more water in response to Ang II compared with females."	( Santollo, J, 2017)
"The dose of 5 g/kg body weight is the optimal dose for anti-exercise-fatigue activity and promotion of sexual interest in male mice."	( Cao, H; Cui, X; Guo, H; Guo, S; Han, C; Li, Y; Xi, X; Xu, F; Zheng, M, 2018)
"Increasing body weight is associated with significantly lower β-hCG and progesterone concentrations in early pregnancy after blastocyst single-embryo transfer in both fresh and frozen cycles."	( Cox, TW; Eyck, PT; Mejia, RB; Nguyen, EB; Sparks, AE; Summers, KM; Van Voorhis, BJ, 2018)
"Understanding how body weight is regulated at the molecular level is essential for treating obesity."	( Apelblat, D; Cohen-Sharir, Y; den Hertog, J; Elson, A; Knobler, H; Kuperman, Y; Spiegel, I, 2019)
"A gain in body weight is seen in those with favourable response."	( Agarwal, R; Aggarwal, AN; Chakrabarti, A; Choudhary, H; Dhooria, S; Garg, M; Sehgal, IS, 2019)
"Body weight is the primary covariate in pharmacokinetics of many drugs and dramatically changes during the first weeks of life of neonates."	( Allegaert, K; Cook, SF; Krzyzanski, W; Sherwin, CMT; van den Anker, JN; Vermeulen, A; Wilbaux, M, 2019)
"Increased body weight is a major factor that interferes with smoking cessation."	( Diéguez, C; Domingos, AI; Fernández-Real, JM; Folgueira, C; Garrido-Gil, P; Iglesias-Rey, R; Labandeira-García, JL; Liñares-Pose, L; López, M; Malone, SA; Martínez-Sánchez, N; Medina-Gomez, G; Moreno-Navarrete, JM; Morgan, DA; Nogueiras, R; Rahmouni, K; Rial-Pensado, E; Romero-Picó, A; Senra, A; Seoane-Collazo, P; Sobrino, T; Tomasini, N, 2019)
"Increased body weight is more common in patients with late-onset psoriasis."	( Grabnar Peklar, D; Habjanič, N; Kerec-Kos, M; Lužar-Stiffler, V, 2019)
"Body weight is a factor, with body weight perception a mediator, toward being a victim of bullying."	( Abdul Aziz, NS; Ahmad, FH; Ganapathy, SS; Hashim, MH; Salleh, R; Saminathan, TA; Sooryanarayana, R; Tan, L, 2019)
"The assumption that body weight is a predictor of fluid intake is often used as rationale for normalizing intake to body weight when examining sex differences in drinking behavior."	( Edwards, AA; Santollo, J, 2021)
"A lower body weight is a significant risk factor for apalutamide-related cutaneous adverse events and their onset is within 6 months of initiation of therapy."	( Asahina, A; Egawa, S; Hata, K; Katsuta, M; Kimura, T; Murakami, M; Nobeyama, Y; Onuma, H; Sugaya, S; Tashiro, K; Watanabe, Y; Yamamoto, T; Yanagisawa, T, 2022)
"Higher body weight is known to negatively impact plasma vitamin C status."	( Block, G; Carr, AC; Lykkesfeldt, J, 2022)
"Total body weight is the sole negative predictor of afXa level, supporting a role for weight-based enoxaparin dosing."	( Acarturk, TO; Ambani, SW; Bengur, FB; Cruz, C; Gimbel, ML; Kubik, MW; Manders, EK; Nguyen, VT; Solari, MG; Sridharan, S; Varelas, LJ, 2022)
"The average body weight is smaller in Asian patients compared with Western patients, but influence of body weight in antibiotic dosing is unknown."	( Jang, SM; Lewis, SJ; Rhie, SJ, 2022)
"GFR, age, and body weight are the main predictors of future urine output in patients taking TVP."	( de la Rosa, RE; García, AIM; García, EM; Moyano, AP; Oporto, FR; Utiel, FJB, 2023)
"Body weight is tightly regulated when outside the normal range."	( Anesten, F; Bellman, J; Dickson, SL; Hägg, D; Jansson, JO; Jansson, PA; Ohlsson, C; Schéle, E; Zlatkovic, J, 2023)

Excerpt

Reference

"High body weight is associated with increased production of oestrogens which may influence the clinical behaviour of breast cancer."

( Howell, A; Jones, M; Williams, G, 1988)

"Body weight is reduced in all treated rats (except the low dose of CA) by day 17 of gestation, with greater weight reductions occurring in rats receiving the higher dose level of each steroid."

( Brundage, M; Dearden, LC; Jansons, R; Mosier, HD; Thai, C, 1986)

"The deficits in body weight are explained, in part, by decreased intake of the semipurified diet, most likely attributable to its high sucrose content."

( Greene, FE; Griffith, JW; Halperin-Walega, ES; Shively, CA, 1985)

"Fat-free body weight is usually calculated by difference and serves as a reference for some physiological functions."

( Buskirk, ER; Mendez, J, 1984)

"Because body weight is a highly integrated physiological variable, it is postulated that various diets which affect survivorship would affect body weight frequency distribution similarly."

( Economos, AC; Miquel, J, 1980)

"The increase in body weight is reduced in the animals treated."

( Bien, E; Buntrock, P; Neubauer, J; Skorka, G, 1981)

"Ferring) per kg body weight are given intramuscularly."

( Hofmann-Ehrhart, B; Kluge, M; Schulz, U; Waldhauser, F; Wandl-Vergesslich, K, 1995)

"Excess body weight is associated with deleterious changes in the lipoprotein profile."

( Denke, MA; Grundy, SM; Sempos, CT, 1993)

"Body weight is closely related to several known cardiovascular risk factors, but it may also have an independent effect on the risk of coronary heart disease (CHD)."

( Jousilahti, P; Pekkanen, J; Puska, P; Tuomilehto, J; Vartiainen, E, 1996)

"Food intake and body weight are determined by a complex interaction of regulatory pathways."

( Al-Haider, W; Beinborn, M; Bonner-Weir, S; Kanarek, R; Kopin, AS; Mathes, WF; McBride, EW; Nguyen, M; Schmitz, F, 1999)

"Since the body weight is known to influence leptin concentrations, the hormone was measured in rats with a very similar body weight (about 250 g) throughout this study."

( Suda, T; Watanobe, H, 1999)

"Age and total body weight are important factors influencing digoxin clearance in children."

( Higuchi, S; Minemoto, M; Suematsu, F; Yukawa, E, 1999)

"Body weight is an important attribute of any animal and influences its biology in many ways."

( Müller, AE, 1999)

"Reducing body weight is one of the effective measures to prevent and treat gout or hyperuricemia in the elderly."

( Tang, D; Xia, B, 1998)

"Elevated body weight is a risk factor for postmenopausal breast cancer and is associated with increased incidence of spontaneous and chemically induced mammary tumors (MTs) in rodents."

( Christensen, TA; Cleary, MP; Getzin, SC; Grande, JP; Jacobson, MK; Jacobson, TL; Juneja, SC; Maihle, NJ; Phillips, FC, 2003)

"Body weight is a good indicator of a person's size and is widely used in clinical assessment."

( Mozumdar, A; Roy, SK, 2004)

"Changes in body weight are the result of changes in energy intake, energy expenditure, or both."

( Bray, GA; De Jonge, L; Li, Y; Smith, SR; Volaufova, J; Xie, H, 2005)

"The body weight is therefore a very sensitive parameter in the surveillance and management of Trypanosome infections especially in Yankasa ewes as experimental animal models."

( Adenowo, TK; Njoku, CO; Oyedipe, EO; Sannusi, A, 2004)

"Body weight is a significant predictor of bone mass."

( Baek, KH; Choi, MG; Ihm, SH; Kang, MI; Lee, WY; Oh, KW; Park, CY; Park, SW; Rhee, EJ; Yoo, HJ; Yoon, KH; Yun, EJ, 2005)

"The body weight is driven by a decrease in food intake with the magnitude of the loss of body weight being directly related to the length of time of exposure to short photoperiod."

( Barrett, P; Mercer, JG; Morgan, PJ; Ross, AW, 2006)

"In conclusions, body weight is the primary covariate factor in pediatric patients."

( Kaibara, A; Katashima, M; Kawamura, A; Tabata, K; Tanigawara, Y, 2006)

"Body weight is the only demographic factor that could be related to lopinavir exposure; clinicians should be alert for an increased risk of suboptimal antiviral efficacy in patients with high body weight, and for an increased risk of toxicity in patients with a low body weight."

( Burger, DM; Koopmans, PP; la Porte, CJ; van der Leur, MR, 2006)

"Preoperative body weight is a reliable predictor of post-RYGBP weight loss."

( Czupryniak, L; Kumor, A; Loba, J; Pawlowski, M; Strzelczyk, J; Szymanski, D, 2007)

"The reduction in body weight is sustained following dosing for 40 days, and it is accompanied by an increase in plasma adiponectin."

( Buckholz, TM; Claus, TH; DeCarr, LB; Livingston, JN; Lumb, KJ; Mahle, CD; Mays, MR; Milardo, LF; Ortiz, AA, 2007)

"Body weight is tightly regulated by a feedback mechanism involving peripheral adiposity signals and multiple central nervous system neurotransmitter pathways."

( Benoit, SC; Clegg, DJ; Reizes, O, 2008)

"The regulation of body weight is carried out by the central nervous system in a complex and redundant way, characterized by interconnections and overlaps with other neuroendocrine functions, such as growth, thyroid and adrenal function, memory, addictive and reward mechanisms."

( Csongrádi, E; Juhász, A; Katona, E; Paragh, G, 2007)

"Loss of body weight is associated with bone loss, and body weight gain is associated with increased bone formation."

( Ferrari, SL; Hamrick, MW, 2008)

"The development of body weight is determined by different factors, namely genetic, behavioral, parental and physiological."

( Bouwman, F; Mariman, E; Nieuwenhuizen, AG; Rutters, F; Vogels, N; Westerterp-Plantenga, MS, 2008)

"Body weight is positively correlated with bone mass and density, and both muscle mass and body fat are thought to play a role in regulating bone metabolism."

( Ding, KH; Ferrari, SL; Hamrick, MW; Isales, CM; Ponnala, S, 2008)

"Body weight is regulated by complex neurohormonal interactions between endocrine signals of long-term adiposity (e."

( Anderson, CM; Baron, AD; Cole, RL; Koda, JE; Parkes, DG; Roland, BL; Roth, JD; Trevaskis, JL; Weyer, C, 2008)

"Regulation of body weight is closely linked to the mass and function of individual body components."

( Bosy-Westphal, A; Haas, V; Heller, M; Later, W; Müller, MJ, 2009)

"Body weight is an important risk factor for thromboses and is used in algorithms to determine dosages in prophylaxis."

( Grohs, JG; Lunzer, A; Vavken, P, 2009)

"Body weight is tightly controlled in a species-specific range from insects to vertebrates and organisms have developed a complex regulatory network in order to avoid either excessive weight gain or chronic weight loss."

( Brüning, JC; Könner, AC; Sánchez-Lasheras, C, 2010)

"The heritability of body weight is high, and genetic variation plays a major role in determining the interindividual differences in susceptibility or resistance to the obesogenic environment."

( Farooqi, IS; Ramachandrappa, S, 2011)

"Body weight is found the most closely related factor to the insulin dosage."

( Dong, JJ; Liao, L; Mou, YR; Qiu, LL; Yang, M; Zhao, JJ, 2010)

"Food intake and body weight are controlled by a variety of central and peripheral factors, but the exact mechanisms behind these processes are still not fully understood."

( Breit, SN; Brown, DA; Herzog, H; Johnen, H; Kuffner, T; Lin, S; Macia, L; Nguyen, AD; Sainsbury, A; Shi, YC; Tsai, VW, 2012)

"Body weight is determined by the balance between energy intake and energy expenditure."

( Cotter, PD; Korpela, R; McAllan, L; Nilaweera, KN; Roche, HM, 2013)

"The body weight is closely dependent on the thyroid status and its maintenance seems to involve thyroid action on mechanisms other than feeding and metabolic rate."

( Alva-Sánchez, C; Fregoso-Aguilar, T; Pacheco-Rosado, J; Villanueva, I, 2012)

"Body weight is a predictor of clopidogrel response."

( Angiolillo, DJ; Bergmeijer, TO; Brown, P; Erlinge, D; Jakubowski, JA; James, S; Moser, BA; Small, DS; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C, 2014)

"When total body weight is used, low BMI tended to be associated with amikacin underdosing."

( Bouadma, L; Chemam, S; de Montmollin, E; Gault, N; Mariotte, E; Massias, L; Mourvillier, B; Papy, E; Sonneville, R; Tubach, F; Wolff, M, 2014)

"Both glucose and body weight are regulated by the brain, which contains GLP1 receptors (GLP1R)."

( D'Alessio, DA; Gutierrez-Aguilar, R; Sandoval, DA; Scott, M; Seeley, RJ; Sisley, S, 2014)

"Body weight is a highly heritable trait across species."

( Farooqi, S, 2014)

"Body weight is a better predictor of anti-Xa levels compared to lean body weight."

( Brandjes, DP; Celik, F; Gerdes, VE; Hooijberg, JH; Huitema, AD; van de Laar, AW, 2015)

"Division by total body weight is the usual way to standardise peak oxygen uptake (peak VO2) for body size."

( Hassinen, M; Komulainen, P; Krachler, B; Lakka, TA; Rauramaa, R; Savonen, K, 2015)

"Body weight is determined via both metabolic and hedonic mechanisms."

( Korner, J; Mechanick, JI; Peterli, R; Vasselli, JR; Yu, YH; Zhang, Y, 2015)

"Body weight is perhaps not as well known as a variable affecting VKA dose."

( Sakaan, S; Sands, CW; Self, TH; Wallace, JL, 2015)

"Body weight is maintained via a complex integration of endocrine and neuronal inputs that regulate the control of orexigenic and anorexigenic neuropeptides in the arcuate nucleus of the hypothalamus."

( Benite-Ribeiro, SA; Putt, DA; Santos, JM; Soares-Filho, MC, 2016)

"Body weight is the strongest predictor of procedural heparin requirement during left atrial ablation in patients on uninterrupted rivaroxaban, even in those with an elevated INR."

( Barbhaiya, CR; Chinitz, JS; Churchill, T; Enriquez, AD; Gautam, S; John, RM; Koplan, BA; Kumar, S; Michaud, GF; Stevenson, WG; Tedrow, UB, 2017)

"Body weight is highly associated with overall health status."

( Abdul Manan, NS; Ahmad, A; Ahmed, A; Mohd Amin, R; Shahril, MR; Syed Abdullah, EF; Syed Saadun Tarek Wafa, SW; Zulaily, N, 2017)

"Renal function and body weight are important when considering the need for alternative dosing regimens."

( Ikeda, K; Lipman, J; Naik, BI; Roberts, JA; Roger, C; Todorovic, MS; Wallis, SC, 2017)

"When differences in body weight are corrected for in the appropriate circumstances, we found that males consume more water in response to Ang II compared with females."

( Santollo, J, 2017)

"The dose of 5 g/kg body weight is the optimal dose for anti-exercise-fatigue activity and promotion of sexual interest in male mice."

( Cao, H; Cui, X; Guo, H; Guo, S; Han, C; Li, Y; Xi, X; Xu, F; Zheng, M, 2018)

"Increasing body weight is associated with significantly lower β-hCG and progesterone concentrations in early pregnancy after blastocyst single-embryo transfer in both fresh and frozen cycles."

( Cox, TW; Eyck, PT; Mejia, RB; Nguyen, EB; Sparks, AE; Summers, KM; Van Voorhis, BJ, 2018)

"Understanding how body weight is regulated at the molecular level is essential for treating obesity."

( Apelblat, D; Cohen-Sharir, Y; den Hertog, J; Elson, A; Knobler, H; Kuperman, Y; Spiegel, I, 2019)

"A gain in body weight is seen in those with favourable response."

( Agarwal, R; Aggarwal, AN; Chakrabarti, A; Choudhary, H; Dhooria, S; Garg, M; Sehgal, IS, 2019)

"Body weight is the primary covariate in pharmacokinetics of many drugs and dramatically changes during the first weeks of life of neonates."

( Allegaert, K; Cook, SF; Krzyzanski, W; Sherwin, CMT; van den Anker, JN; Vermeulen, A; Wilbaux, M, 2019)

"Increased body weight is a major factor that interferes with smoking cessation."

( Diéguez, C; Domingos, AI; Fernández-Real, JM; Folgueira, C; Garrido-Gil, P; Iglesias-Rey, R; Labandeira-García, JL; Liñares-Pose, L; López, M; Malone, SA; Martínez-Sánchez, N; Medina-Gomez, G; Moreno-Navarrete, JM; Morgan, DA; Nogueiras, R; Rahmouni, K; Rial-Pensado, E; Romero-Picó, A; Senra, A; Seoane-Collazo, P; Sobrino, T; Tomasini, N, 2019)

"Increased body weight is more common in patients with late-onset psoriasis."

( Grabnar Peklar, D; Habjanič, N; Kerec-Kos, M; Lužar-Stiffler, V, 2019)

"Body weight is a factor, with body weight perception a mediator, toward being a victim of bullying."

( Abdul Aziz, NS; Ahmad, FH; Ganapathy, SS; Hashim, MH; Salleh, R; Saminathan, TA; Sooryanarayana, R; Tan, L, 2019)

"The assumption that body weight is a predictor of fluid intake is often used as rationale for normalizing intake to body weight when examining sex differences in drinking behavior."

( Edwards, AA; Santollo, J, 2021)

"A lower body weight is a significant risk factor for apalutamide-related cutaneous adverse events and their onset is within 6 months of initiation of therapy."

( Asahina, A; Egawa, S; Hata, K; Katsuta, M; Kimura, T; Murakami, M; Nobeyama, Y; Onuma, H; Sugaya, S; Tashiro, K; Watanabe, Y; Yamamoto, T; Yanagisawa, T, 2022)

"Higher body weight is known to negatively impact plasma vitamin C status."

( Block, G; Carr, AC; Lykkesfeldt, J, 2022)

"Total body weight is the sole negative predictor of afXa level, supporting a role for weight-based enoxaparin dosing."

( Acarturk, TO; Ambani, SW; Bengur, FB; Cruz, C; Gimbel, ML; Kubik, MW; Manders, EK; Nguyen, VT; Solari, MG; Sridharan, S; Varelas, LJ, 2022)

"The average body weight is smaller in Asian patients compared with Western patients, but influence of body weight in antibiotic dosing is unknown."

( Jang, SM; Lewis, SJ; Rhie, SJ, 2022)

"GFR, age, and body weight are the main predictors of future urine output in patients taking TVP."

( de la Rosa, RE; García, AIM; García, EM; Moyano, AP; Oporto, FR; Utiel, FJB, 2023)

"Body weight is tightly regulated when outside the normal range."

( Anesten, F; Bellman, J; Dickson, SL; Hägg, D; Jansson, JO; Jansson, PA; Ohlsson, C; Schéle, E; Zlatkovic, J, 2023)

Context

Excerpt	Reference
"The body weight has a bearing on the level of risk factors, i."	( Grafnetter, D; Jirkovská, A; Karasová, I; Pelikánová, J; Válek, J; Vlasáková, Z, 1990)
"Ten days later the body weight has reached the starting value again and the IRI secretion shows again signs of hyperinsulinism."	( Bierwolf, B; Blech, W; Weiss, I; Ziegler, M, 1986)
"Rabbits under 1 kg body weight have larger blood volumes than would be expected from their anaemia alone, were the relationship deduced in rabbits over 1 kg in body weight applicable."	( Mott, JC, 1967)
"Increased body weight has no influence on the insulin resistance observed in chronic liver inflammation."	( Bleyl, H; Knecht, M; Matthes, K; Oehler, G, 1981)
"The average body weight have a significantly reduce and after six months averagely reduced 5."	( Gao, Y; Liu, X; Sun, L; Wang, C; Zhu, D, 2013)
"Increased body weight has been associated with low thyroxine concentrations in non-pregnant women."	( Gowachirapant, S; Melse-Boonstra, A; Winichagoon, P; Zimmermann, MB, 2014)
"Body weight has a significant impact on blood volume and drug clearance."	( Ashrani, A; Bockenstedt, PL; Chesney, C; Eby, C; Engh, AM; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ; Hendrie, P; Holmstrom, B; Kuderer, N; Lee, A; Lee, JT; Lovrincevic, M; McMillian, N; Millenson, MM; Neff, AT; Ortel, TL; Paschal, R; Shattil, S; Siddiqi, T; Smock, KJ; Soff, G; Streiff, MB; Wang, TF; Yee, GC; Zakarija, A, 2015)

Excerpt

Reference

"The body weight has a bearing on the level of risk factors, i."

( Grafnetter, D; Jirkovská, A; Karasová, I; Pelikánová, J; Válek, J; Vlasáková, Z, 1990)

"Ten days later the body weight has reached the starting value again and the IRI secretion shows again signs of hyperinsulinism."

( Bierwolf, B; Blech, W; Weiss, I; Ziegler, M, 1986)

"Rabbits under 1 kg body weight have larger blood volumes than would be expected from their anaemia alone, were the relationship deduced in rabbits over 1 kg in body weight applicable."

( Mott, JC, 1967)

"Increased body weight has no influence on the insulin resistance observed in chronic liver inflammation."

( Bleyl, H; Knecht, M; Matthes, K; Oehler, G, 1981)

"The average body weight have a significantly reduce and after six months averagely reduced 5."

( Gao, Y; Liu, X; Sun, L; Wang, C; Zhu, D, 2013)

"Increased body weight has been associated with low thyroxine concentrations in non-pregnant women."

( Gowachirapant, S; Melse-Boonstra, A; Winichagoon, P; Zimmermann, MB, 2014)

"Body weight has a significant impact on blood volume and drug clearance."

( Ashrani, A; Bockenstedt, PL; Chesney, C; Eby, C; Engh, AM; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ; Hendrie, P; Holmstrom, B; Kuderer, N; Lee, A; Lee, JT; Lovrincevic, M; McMillian, N; Millenson, MM; Neff, AT; Ortel, TL; Paschal, R; Shattil, S; Siddiqi, T; Smock, KJ; Soff, G; Streiff, MB; Wang, TF; Yee, GC; Zakarija, A, 2015)

Actions

Excerpt	Reference
"Fetal body weight was affected at lower daily doses than in previously published studies, possibly due to the longer total exposure period and/or lack of a recovery period between cessation of exposure and termination."	( George, JD; Jahnke, GD; Marr, MC; Myers, CB; Price, CJ, 2000)
"Changes in body weight can affect the overall health of an older patient and should not be considered a normal part of the aging process."	( Avena-Woods, C; Hilas, O, 2014)
"We observed that body weight affects the trends in the MEP concentrations significantly among children (aged 6-11 years), adolescents (aged 12-19 years) and adults (aged 20-49 years)."	( Aylward, L; Guay, M; Saravanabhavan, G; Walker, M, 2014)
"Given that body weight was affected by the drug regardless of diet while food intake was selectively altered in palatable diet fed animals, these results raise the possibility that i."	( Bobilev, A; Branch, A; Cai, H; Negrao, NW; Shen, P, 2015)
"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state."	( Devarakonda, K; Franke, R; Morton, T, 2016)
"Changes in body weight may affect energy expenditure (EE) and, thereby, energy requirement."	( Andersen, A; Biourge, V; Blache, D; Dietrich, N; Marcussen, C; Tauson, AH; Theil, PK, 2023)

Excerpt

Reference

"Fetal body weight was affected at lower daily doses than in previously published studies, possibly due to the longer total exposure period and/or lack of a recovery period between cessation of exposure and termination."

( George, JD; Jahnke, GD; Marr, MC; Myers, CB; Price, CJ, 2000)

"Changes in body weight can affect the overall health of an older patient and should not be considered a normal part of the aging process."

( Avena-Woods, C; Hilas, O, 2014)

"We observed that body weight affects the trends in the MEP concentrations significantly among children (aged 6-11 years), adolescents (aged 12-19 years) and adults (aged 20-49 years)."

( Aylward, L; Guay, M; Saravanabhavan, G; Walker, M, 2014)

"Given that body weight was affected by the drug regardless of diet while food intake was selectively altered in palatable diet fed animals, these results raise the possibility that i."

( Bobilev, A; Branch, A; Cai, H; Negrao, NW; Shen, P, 2015)

"Body weight affected variability in V/F, with a predicted value of 193 L in men and 174 L in women for a 72-kg participant at steady state."

( Devarakonda, K; Franke, R; Morton, T, 2016)

"Changes in body weight may affect energy expenditure (EE) and, thereby, energy requirement."

( Andersen, A; Biourge, V; Blache, D; Dietrich, N; Marcussen, C; Tauson, AH; Theil, PK, 2023)

Treatment

Excerpt	Reference
"During the 7 weeks of treatment body weight increased 7 kgrams."	( Böhles, H; Fekl, W; Heid, H; Koch, H, 1977)
"After treatment, whole body weights and wet organ weights of liver, spleen, and kidney, as well as gross and histologic changes in these and other tissues, were monitored on Days 1, 4, 7, 11, 15, 21, and 28."	( Baker, WH; Jackson, WE; Nold, JB; Patchen, ML, 1992)
"Daily corticosterone treatment decreased body weight and food intake."	( Haleem, DJ, 1992)
"During reserpine treatment, body weight and food intake were significantly reduced from the 2nd day on."	( Benrezzak, O; Bérubé, FL; Morisset, J, 1991)
"Survival was not adversely affected by treatment, however, body weight of males and females in the high dose group was significantly lower than that of controls."	( Bendele, AM; Eacho, PI; Foxworthy, PS; Hoover, DM; van Lier, RB, 1990)
"Ethanol pretreatment and body weight had no effect on MEGX levels at any of the time points tested in this model."	( Druckenbrod, RW; Mendenhall, CL; Myre, SA; Schroeder, TJ; Stanberry, EA, 1991)
"Chronic fencamfamine treatment reduced body weight of rats below their normal body weight."	( Aizenstein, ML; DeLucia, R; Planeta, Cda S; Scavone, C, 1987)
"At the end of treatment, body weights were reduced in higher dose groups of sulfasalazine, CH 74A and sulfapyridine compared to control animals."	( Agback, H; Bardin, CW; Didolkar, AK; Johansson, ED; Keizer-Zucker, A; Sundaram, K, 1988)
"Findings suggest that DHEA acetate treatment affected body weight, body composition and utilization of dietary energy by both impairing fat synthesis and promoting fat-free tissue deposition and resting heat production."	( Davis, JR; Tagliaferro, AR; Truchon, S; Van Hamont, N, 1986)
"During three days' treatment, body weight in Group II increased significantly compared with that in Group I (P less than 0."	( Hamada, S; Imura, H; Nakamura, H; Nanno, M; Ohtsuka, R; Yoshimi, T, 1987)
"Bromocriptine treatment reduced body weight and decreased the plasma levels of prolactin, glucagon and insulin, as compared to non-treated tumor-bearing rats."	( Gautvik, K; Haug, E; Johansen, PW; Knudtzon, J, 1986)
"This treatment decreased body weights and increased significantly the relative weights of the hearts."	( Ali, BH; Czarnecki, CM, 1987)
"During the pretreatment period, body weight and plasma tryptophan levels were measured and the Beck Depression Inventory, SCL 90 rating, and Profile-of-Mood State (POMS) were used to assess mood."	( Strain, GW; Strain, JJ; Zumoff, B, 1985)
"Since post-treatment body weight changes correlated with daily food intakes (r = 0."	( Dubuc, PU, 1985)
"There was no effect of treatment on body weights through 12 mo of age."	( Garza, F; Jones, LS; Southern, LL; St George, RL; Thompson, DL, 1985)
"Gestational age, gender, duration of treatment, body weight, and Apgar scores were not found to correlate significantly with theophylline clearance."	( Erkan, NV; Gal, P; Gilman, JT; Hersh, CB; Levine, RS, 1986)
"In the long-term treatment group, body weight showed a slight mean decrease."	( Arberg-Wistedt, A; Jozwiak, H; Nyström, C; von Knorring, L; Wålinder, J, 1983)
"Nestlings and adults with low pretreatment body weights appeared to be more vulnerable to organophosphate (OP) exposure."	( Grue, CE; Shipley, BK, 1984)
"On the other hand, from days 5 to 14 of treatment, body weight and food intake increased, though they were still lower than in sham-operated controls."	( Faure, A; Sutter, BC; Sutter-Dub, MT; Vergnaud, MT, 1984)
"The effect of diazepam treatment on body weight was compared to that of vehicle treatment in the following groups: (1) young adult females, (2) pregnant females, (3) shock treated young males (4) nonshocked young males."	( Grimm, VE; Jancourt, A, 1983)
"In the second experiment, GBL-treated rats had body weights similar to those of control rats, but testicular weights were significantly decreased."	( Debeljuk, L; Díaz, MD; Maines, VM; Seilicovich, A, 1983)
"After 4 weeks of treatment, the body weight increase was similar in all treated groups."	( Broer, Y; Fouchereau-Peron, M; Rosselin, G, 1981)
"At the end of 7 and 14 days treatment period, body weight gain, serum protein, serum glucose, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) were measured."	( Boykin, M; Butts, A; Chapatwala, KD; Rajanna, B, 1982)
"At the end of the treatments, the body weight gains, serum glucose, serum protein, serum glutamic oxalacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) were determined."	( Chapatwala, KD; Desaiah, D; Rajanna, B, 1980)
"In 38 patients investigated before treatment body weight was normal while mean TBK was 91% of predicted in men and 100% in women."	( Attman, PO; Ewald, J; Isaksson, B, 1980)
"In the lean rats, (-)-hydroxycitrate treatment decreased body weight, food intake, percent of body fat, and fat cell size."	( Blase, D; Cleary, MP; Greenwood, MR; Gruen, R; Stern, JS; Sullivan, AC; Triscari, J, 1981)
"During 1 year of treatment body weight fell by 11."	( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994)
"In the duodenum, PGE2 treatment (4 mg/kg body weight) produced a significant increase in crypt depth (35%, p < 0."	( Fernandez-Otero, MP; Marti, A, 1994)
"During the luteal phase of the pretreatment cycle, body weight and blood pressure were recorded, and plasma levels of the following variables were recorded: sex-hormone-binding globulin (SHBG), cortisol-binding globulin (CBG), testosterone, free testosterone, dihydrotestosterone, androstenedione, dihydroepiandrosterone sulfate (DHEAS), and hydroxyprogesterone."	( Borm, GF; Coenen, CM; Rolland, R; Thomas, CM, 1995)
"In OVX rats treated with DRO, body weight decreased significantly in a dose-response manner, and total serum cholesterol was significantly reduced by 65% to 70% compared to both sham and OVX controls."	( Chen, HK; Jee, WS; Ke, HZ; Ma, YF; Pirie, CM; Qi, H; Simmons, HA; Thompson, DD, 1995)
"Non-transgenic control mice were treated similarly."	( Murray, JD; Oberbauer, AM; Pomp, D, 1996)
"At 72 hr after treatment, body weight gain was significantly decreased in the 100 mg/kg CIS group and in all CT dose groups."	( Elwell, MP; Jeter, SP; Morgan, DL; Moskowitz, PD; Price, HC; Shines, CJ; Wilson, RE, 1995)
"Aldosterone (type I agonist) treatment increased body weight gain and returned energy accretion to the level of sham-operated animals."	( Edwards, GL; Martin, RJ; White, BD, 1996)
"After stopping the treatment, the body weight and food consumption in the diazepam 100 and 300 mg/kg groups tended to decrease or decreased to values lower than those in the control group, whereas these parameters in the S-(+)-DN-2327 30, 100 and 300 mg/kg groups were comparable to the control group values."	( Awasaki, Y; Inui, Y; Nishida, N; Yamamoto, M, 1996)
"Post-treatment body weights were approximately 5% greater in the CL group compared to CON (P < 0."	( Criswell, DS; Herb, RA; Powers, SK, 1996)
"After a median of 176 days on treatment, body weight had increased in 119 out of the 160 patients followed (74."	( Aussel, C; Beaugerie, L; Carbonnel, F; Carrat, F; Cosnes, J; Gendre, JP; Girard, PM; Gobert, JG; Maslo, C; Rozenbaum, W; Wirbel, E, 1998)
"After 4-wk of treatment, the body weight of the ethanol group was 7% and of the pair-fed rats 19% lower than that of the absolute controls."	( Benický, J; Brtko, J; Nikodémová, M; Strbák, V, 1998)
"Following Aroclor 1254 treatment, body weight gain in the high-dose group was significantly lower than the control and low-dose groups."	( Barone, S; Choksi, NY; Derr-Yellin, EC; Herr, DW; Kodavanti, PR; MacPhail, RC; Mundy, WR; Shafer, TJ; Tilson, HA, 1998)
"There was no effect of oxytocin treatment on body weight or weight gain in either of the feeding groups."	( Bang, P; Brismar, K; Carlsson-Skwirut, C; Sohlström, A; Uvnäs-Moberg, K, 1999)
"At the termination of the treatment, the body weight of SAM P8 was markedly lower than that of the equal aged senescence-resistant prone 1 (SAM R1), but this was conspicuously recovered to the level of SAM R1 by SDT treatment."	( Joo, HJ; Jung, KY; Lee, MY; Ma, JY; Park, JH; Yang, JM, 1999)
"After treatment, body weight was approximately 10% greater in Ovx than in Sham rats (P < 0."	( Brown, M; Fisher, JS; Kohrt, WM, 2000)
"Within the Cd plus MLT-treated group, the body weight gains and relative thymus weights were significantly increased when compared with the treatment of Cd alone."	( Ahn, YK; Kim, JH; Kim, YO, 2000)
"Chronic exendin-4 treatment reduced body weight in both obese and lean Zucker rats by reducing food intake: metabolic rate was apparently suppressed."	( Al-Barazanji, KA; Arch, JR; Buckingham, RE; Tadayyon, M, 2000)
"Within the Pb plus MLT-treated group, the body weight gains and the relative thymus weights were significantly increased when compared with the treatment of Pb alone."	( Kim, JH; Kim, YO; Pyo, MY, 2000)
"Drug treatment affected body weight, glandular weight, DNA synthesis, and the concentration of soluble and structural membrane proteins."	( Cowman, RA; Humphreys-Beher, MG; Koller, MM; Scarpace, PJ, 2001)
"Six replicates were allotted to each treatment."	( Lefrançois, MR; Nahas, J, 2001)
"After treatment, body weight largely recovered to 90-95% of controls."	( Broening, HW; Fukumura, M; Inman-Wood, SL; Morford, LL; Vorhees, CV, 2001)
"Five days of lycopene pretreatment (10 mg/kg body weight, ip) almost completely prevented liver biomolecule oxidative damage and protected the tissue against the observed histological alterations."	( Capelozzi, VL; Gomes, OF; Mascio, PD; Matos, HR; Medeiros, MH, 2001)
"Before and after the 3-month treatment with CAM, body weight, serum levels of interleukin-6 (IL-6, a cytokine which, together with TNF-alpha, plays a crucial role in the development of cancer cachexia), total protein, albumin, cholinesterase and hemoglobin were measured for the evaluation of the patients' clinical status."	( Hamada, K; Kita, E; Konishi, M; Maeda, K; Majima, T; Mikasa, K; Narita, N; Sakamoto, M, 2001)
"Cows were blocked by pretreatment body weight and energy-corrected milk (ECM) and assigned to control, SHSL (20."	( DeFrain, JM; Ethington, RT; Park, AF; Shirley, JE; Titgemeyer, EC, 2002)
"There was no effect of any treatment on body weight; however, there was a significant reduction in both food and fluid intake in fatty groups treated with BEOV."	( Battell, ML; Bhanot, S; McNeill, JH; Orvig, C; Yuen, VG, 2003)
"Post-treatment body weights and skeletal muscle weights were not affected by clenbuterol treatment."	( Bigard, AX; Bricout, VA; Serrurier, BD, 2004)
"In STZ-treated rats body weight decreased and plasma glucose and glycosylated hemoglobin increased."	( Bergren, DR; Rendell, MS, 2004)
"Fenofibrate treatment decreased body weight gain and WAT mass in OVX, but not in Sham mice."	( Choi, JH; Han, M; Jeong, S; Kim, BH; Kim, J; Kim, M; Lee, H; Nam, KH; Nicol, CJ; Oh, GT; Yoon, M, 2004)
"Both groups of oleoyl-estrone-treated rats lost body weight, energy, and lipid; the losses in the rats receiving tamoxifen alone were less marked than in those receiving oleoyl-estrone."	( Alemany, M; Fernández-López, JA; Ferrer-Lorente, R; García-Peláez, B; Remesar, X, 2004)
"Up to 90 days daily oral crude neem oil treatment (5 g/kg body weight) of laboratory mice did not cause any significant changes in weekly body weight gain, nor in serum liver damage indicators, direct bilirubin or total bilirubin."	( Awad, OM, 2003)
"There was no effect of treatment on body weight at PN115."	( Mooney, SM; Napper, RM, 2005)
"Fluoxetine treatment reduced body weight within the first 24 h of treatment."	( Grossie, B; Hensler, JG; Sarkar, J; Uphouse, L, 2006)
"Following the treatment period, body weight gain was identical in the four groups."	( Berthelot, A; Figard, H; Gaume, V; Mougin, F, 2006)
"Insulin treatment reversed body weight loss and corrected hyperglycemia at diabetic rats as expected."	( Chen, M; Georgeson, KE; Harmon, CM; Loux, TJ; Yang, YK, 2006)
"After the treatment, lung/body weight ratio in the mutant strain was significantly larger than that in the wild-type mice."	( Akishita, M; Horiuchi, M; Oishi, Y; Oshima, T; Ozono, R; Yoshizumi, M, 2006)
"Birds on FWD treatment lost more body weight during the molting period, but gained more after molt compared to thyroxine treatments (P<0."	( Bass, PD; Hooge, DM; Koutsos, EA, 2007)
"Open-label sibutramine treatment decreased body weight 4."	( Diedrich, A; Engeli, S; Heusser, K; Janke, J; Jordan, J; Luft, FC; Tank, J; Wiesner, S, 2007)
"Following maprotiline treatment, the body weight and BMI were significantly increased (P=0."	( Chen, YC; Chou, CH; Hung, YJ; Perng, CH; Shen, YC; Yeh, CB, 2007)
"Metformin may safely assist olanzapine-treated patients in body weight and carbohydrate metabolism control."	( Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M, 2007)
"At 26, 39, or 52 weeks of treatment, body weight gain was significantly reduced by 7."	( Bagchi, D; Bagchi, M; Barrett, L; Bramble, JD; Chatterjee, A; Kincaid, AE; Limpach, AL; Norton, N; Sandstrom, R; Shara, M; Tran, J; Yasmin, T, 2007)
"Leptin treatment reduced body weight of both MHF diet- and chow-fed male mice but failed to prevent the decrease in Y(1)R/LacZ transgene expression apparent in the DMH and VMH of male mice after 8 weeks of MHF diet intake."	( Eva, C; Panzica, G; Zammaretti, F, 2007)
"However, many antidiabetic treatments increase body weight."	( Golay, A, 2008)
"Days in milk were similar between treatments, and body weight and milk yield were unaffected by treatment."	( Cobb, C; Hill, SR; Knowlton, KF; Taylor, MS; Wilson, KF, 2007)
"In conclusion, DHEA treatment decreases body weight and adiposity in old female rats fed a high-fat diet, leading to an improvement of the HOMA index for insulin sensitivity, with decreasing circulating insulin levels, and preventing the age-associated decline of visceral-adipose adiponectin expression."	( Garaulet, M; Palou, A; Pérez-Heredia, F; Portillo, MP; Priego, T; Sánchez, J; Zamora, S, 2008)
"After 3-week Rhodiola rosea treatment, the body weight and 1% sucrose intake increased in rats of the low-dose Rhodiola rosea group and recovered to the level of the normal control group."	( Chen, QG; Chen, SJ; Qin, YJ; Tang, JY; Zeng, YS; Zhong, ZQ, 2008)
"In PPSBPE treated mice the body weight was not reduced in contrast to that in vehicle group."	( Badole, SL; Bodhankar, SL, 2009)
"Captopril treatment decreased body weight in the first 2 weeks of treatment."	( Begg, DP; Jois, M; Spark, KJ; Stanley, TK; Weisinger, HS; Weisinger, RS, 2009)
"The effects of chronic rimonabant treatment on body weight gain occurred irrespective of diet-induced changes in lipogenic activity, food intake and daily energy expenditure, and were, in fact, most pronounced in HF/FO mice."	( Bloks, VW; Jonas, I; Koolman, AH; Kuipers, F; Oosterveer, MH; Sauer, PJ; van Dijk, G, 2010)
"After 20 treatments, the body weight, waistline, and the serum total cholesterol (TC), the fasting triglyceride (TG) and low-density lipoprotein (LDL) were significantly changed (P < 0."	( Wu, ZH, 2009)
"Dexamethasone treatment evoked body weight loss (-24%), followed by muscular atrophy in the tibialis anterior (-25%) and the extensor digitorum longus (EDL, -15%)."	( Barel, M; Bosqueiro, JR; do Amaral, SL; Giozzet, VA; Perez, OA; Rafacho, A, 2010)
"In contrast, insulin treatment increased body weight (1."	( Aronoff, S; Blevins, T; Chen, S; Han, J; Nicewarner, D; Oliveira, JH, 2010)
"Adult male Wistar rats were either pre-treated with 2 mg/g body weight (BW) of powdered P."	( Dolder, H; Leite, RP; Monteiro, JC; Predes, FS; Wada, RS, 2011)
"After 4 weeks of drug treatment, body weights were noted and random blood glucose and insulin was estimated for the antidiabetic effect."	( Arumugam, S; Davis, JA; Misra, CS; Ray, A; Roy, S; Shah, V; Sharma, S; Shirumalla, RK, 2011)
"The rats in reserpine treated group, body weight, concentrations of IFN-γ, IL-1 and TNF-α in serum, expression of TGF-β in small intestine, VIP in small intestine decreased (P<0."	( Guo, Y; Jia, H; Liu, Z; Lu, A; Xu, S; Zha, Q; Zhang, W; Zhao, N, 2011)
"Sitagliptin treatment reduced body weight without changes in overall body mass index or in the epididymal and retroperitoneal fat mass."	( Coben, J; Dobrian, AD; Galkina, EV; Leone, KA; Lindsay, JW; Ma, K; Ma, Q; Nadler, JL, 2011)
"In HMB-treated TB, body weight was not lost but significantly (p=0."	( Aversa, Z; Baccino, FM; Bonetto, A; Costelli, P; Lucia, S; Minero, VG; Muscaritoli, M; Penna, F; Rossi Fanelli, F, 2011)
"Exenatide or insulin glargine treatment decreased body weight by 6%."	( Bunck, MC; Cornér, A; Diamant, M; Eliasson, B; Heine, RJ; Shaginian, RM; Smith, U; Taskinen, MR; Yki-Järvinen, H, 2011)
"During treatment, body weight of each pregnant mouse was measured daily."	( Cho, NK; Kim, DH; Kim, JH; Lee, CH; Lee, CK; Lee, JT; Son, BC; Suh, CH, 2011)
"Exenatide treatment reduced body weight and body mass index (BMI) and improved HbA1c, the seven-point glucose profile, and daily mean glucose compared with placebo (P < 0."	( Ding, B; Du, TX; Gao, G; Lee, KO; Ma, JH; Mao, XM; Wu, JD; Xu, XH; Ye, L; Zhu, J, 2011)
"After the eight-week treatment, body weight and body mass index showed to be significantly increased compared to those at baseline."	( Chen, CH; Chen, TT; Chen, VC; Lin, NC; Lin, TY; Lu, ML; Shao, WC, 2011)
"Compared with pre-treatment, the body weight and BMI and serum leptin levels in the control and treatment groups were all decreased significantly (P < 0."	( Li, M; Li, Q; Wang, SJ; Xiao, HL; Xing, HJ; Yang, JJ, 2010)
"The I3C treatment decreased body weight and fat accumulation and infiltrated macrophages in epididymal adipose tissue of DIO mice, and these reductions were associated with improved glucose tolerance and with modulated expression of adipokines and lipogenic-associated gene products, including acetyl coenzyme A carboxylase and peroxisome proliferator-activated receptor-γ."	( Chan, MH; Chang, HP; Chen, YH; Chiu, YS; Wang, ML, 2011)
"After 14 weeks of treatment, body weight, abdominal fat, blood lipid and serum insulin level were measured, and the protein and gene expression of PTP1B in liver tissue was tested."	( Chang, B; Li, M; Liu, WK; Qin, PJ; Tong, XL; Zhen, Z, 2011)
"These results indicate that GSK232802A treatment reduces body weight and adiposity in ovariectomized nonhuman primates by suppressing food intake and increasing activity, particularly in the most sedentary individuals."	( Cameron, JL; Koegler, FH; Shearin, J; Sullivan, EL, 2012)
"Exendin-4 treatment decreased body weight, serum free fatty acid (FA), and triglyceride levels in HF-induced obese C57BL/6J mice."	( Bae, JC; Chae, SW; Choi, JH; Hong, SW; Kim, DH; Kim, SW; Lee, J; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ, 2012)
"In GK rats, 23 days of treatment increased body weight but did not cause hemodilution."	( Gao, W; Jusko, WJ, 2012)
"After the treatment period, body weight decreased (-2."	( Dohi, K; Hoshino, K; Ichikawa, K; Ito, M; Kumagai, N; Machida, H; Nakajima, H; Nakamori, S; Nakamura, M; Nobori, T; Okamoto, S; Onishi, K; Sato, Y; Sugimoto, T; Sugiura, E; Watanabe, K; Yamada, T, 2012)
"In testosterone- and vehicle-treated rats, body weights and food intake did not differ."	( Armstrong, A; Fridkin, V; Jakowec, M; Najafi, A; Shah, V; Wood, RI, 2013)
"In obese mice, after 8-week treatment, the body weight gain was significantly more suppressed by both 1 mg/kg and 2 mg/kg of DA-3091, monthly subcutaneous administered, than by 10 mg/kg/day of sibutramin, a drug against obesity."	( Jun, SW; Kang, JS; Kang, SH; Kwak, HH; Park, YI; Son, JP; Son, MK, 2013)
"The results indicated that neonatal PCP treatment reduced body weight during neonatal and adulthood periods, and did not alter baseline corticosterone levels in both male and female mice."	( Amani, M; Azarfarin, M; Bakhtiari, A; Doosti, MH; Majidi-Zolbanin, N; Mirza-Rahimi, M; Salari, AA; Samadi, H, 2013)
"Corticosterone treatment increased body weight and food intake for the duration of the treatment and increased gonadal and subcutaneous white adipose tissue weight in transient group by +35% and +31%, and in the continuous group by +140% and 110%."	( Auvinen, HE; Biermasz, NR; Havekes, LM; Meijer, OC; Pereira, AM; Princen, H; Rensen, PC; Romijn, JA; Smit, JW; Wang, Y, 2013)
"The results showed that oxymatrine treatment reduced body weight gain, liver weight, liver index, dyslipidemia, and liver triglyceride level in a dose dependant manner."	( Hu, ZJ; Shi, L; Shi, LJ; Song, GY; Wang, C; Zhang, DH; Zhang, HF, 2013)
"In vivo, T3 and T2 treatment induced body weight gain in tilapia."	( Luna, M; Navarrete-Ramírez, P; Orozco, A; Valverde-R, C, 2014)
"After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups."	( Fan, H; Pan, Q; Xu, Y; Yang, X, 2013)
"Our results show that dexamethasone treatment reduced body weight and hippocampal volume transiently during development, but these effects were no longer detected at adulthood."	( de Graan, PN; de Vries, WB; Derks, JB; Hessel, EV; Noorlander, CW; Tijsseling, D; Visser, GH, 2014)
"However, there was no treatment effect on body weight (CON -2."	( Askew, EW; Drummond, MJ; Gershenoff, DC; Wing-Gaia, SL, 2014)
"After 8-week treatment, body weight, wet weight of visceral fat and the percentage of body fat (PBF) were measured."	( Chang, X; Chao, J; Han, S; Huang, Q; Lin, H; Lu, K; Qu, S; Shen, C; Song, X; Tan, M; Wang, C; Xie, S; Xu, L; Yuan, Q; Zhang, J, 2014)
"Preoperative treatment impaired body weight during the gavage period, but was without effect on liver regeneration."	( Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR, 2014)
"During treatment, maternal body weight gain, and food and water intake were evaluated."	( Bernardi, MM; Reis-Silva, TM; Sandini, TM; Spinosa, Hde S; Udo, MS, 2014)
"Dosage, length of treatment, age and body weight of the dogs were recorded as well as any adverse events that occurred during treatment."	( Cook, C; Schmeitzel, L; Short, J; Zabel, S, 2014)
"They were blocked based on pre-treatment body weight (range 22."	( Kellermann, M; Rehbein, S; Wehner, TA, 2014)
"Compared with before treatment, body weight, BMI, waist circumstance, and waist-hip ratio obviously decreased after treatment, showing significant difference when compared with the control group (P < 0."	( Liu, J; Meng, X; Xia, SY; Yu, H; Zhang, P; Zhang, YR, 2014)
"ACE 2 activation treatment lowered body weight (DIZE vs control) (28."	( Andrade, JM; Batista de Paula, AM; de Macedo, SM; Ferreira, AJ; Guimaraes, AL; Guimarares, TA; Sousa Santos, SH, 2015)
"Exendin-4 treatment deceased body weight, serum-free fatty acid, and triglyceride levels in HFD-induced obese C57BL/6J mice."	( Chen, JA; Li, L; Sun, ZL; Wang, SH; Wei, Q, 2015)
"Compared before the treatment, SBP, WC, body weight, BMI, FPG, OG-TT2hBG, FINS, GTT2h insulin, HOMA-IR, TC and LDL-C in the acupuncture group were all significantly reduced (all P <0."	( Liu, Y; Yang, Y, 2015)
"After 12 weeks of treatment ETP, body weight and food intake were analyzed."	( Ainödhofer, H; Cvirn, G; Gruber, HJ; Haybaeck, J; Kieslinger, P; Mangge, H; Obermayer-Pietsch, B; Pailer, S; Prüller, F; Zelzer, S, 2015)
"After two weeks of treatment, body weight, food intake,fasting glucose, impaired glucose tolerance, and other indicators were measured."	( Ding, CY; Shi, NC; Tan, QY, 2015)
"After 8 weeks of treatment, body weight, adipose tissue and liver mass were measured, and liver and plasma lipid levels were determined to evaluate to effect of FSE with or without AS treatment on diet-induced obesity, hyperlipidemia and hepatic steatosis."	( Cheung, DW; Fung, KP; Koon, CM; Lau, CB; Lau, CP; Leung, PC; Ng, CF; Wat, E; Wong, EC, 2016)
"Liraglutide as adjunct to insulin treatment reduced body weight and daily dose of insulin compared with insulin alone."	( Dejgaard, TF; Frandsen, CS; Holst, JJ; Madsbad, S, 2016)
"This treatment increased body weight gain and reduced feed conversion ratio, leading to superior growth performance."	( Chang, CL; Muthamilselvan, T; Yang, CY; Yang, WC, 2016)
"Results showed that (-)-HCA treatment reduced body weight gain and increased feed conversion ratio in rats."	( Han, N; Li, L; Ma, H; Peng, M, 2016)
"After 12 weeks of treatment, body weight, uterine index and the dry weight of thigh‑bones were recorded."	( Huang, KB; Qin, RZ; Yang, XW; Yang, YX; Zhou, QL, 2016)
"Luteolin treatment (15mg/kg body weight, p."	( Barua, CC; Bodduluru, LN; Gogoi, R; Kasala, ER, 2016)
"After the last treatment course, body weight, energy intake, serum lipopolysaccharides (LPS), insulin resistance, and fecal short-chain fatty acids (SCFAs) were compared."	( Gao, Z; Hu, H; Li, X; Liu, G; Mei, X; Wang, Z; Zhang, X; Zou, L, 2016)
"After OTA treatment, the body weight decreased and AST, ALP, TP, and BUN levels in serum increased."	( Gao, J; He, X; Huang, K; Luo, H; Qi, X; Xu, W; Yu, T; Zhu, L, 2016)
"All patients completed the treatment."	( Guo, M; Li, Y; Lu, C, 2016)
"Chronic adiponectin treatment reduced body weight, total cholesterol, free fatty acids, fasting glucose and area under the curve of intraperitoneal glucose tolerance test, compared with HFD rats."	( Fernandes, R; Letra, L; Pereira, A; Seiça, RM; Sena, CM, 2017)
"Before and after drug treatment, body weight was measured and blood was collected for assessment of lipid and liver function profiles."	( Annamalai, S; Dev, A; Mohanam, L; Prabhu, V; Raja, V, 2017)
"The results revealed that CA treatment decreased body weight, fat mass, food intake, and serum lipid, free fatty acid and leptin levels."	( Fang, X; Gao, S; Liu, H; Ma, R; Ma, Y; Mo, F; Mu, Q; Wang, L; Wu, R; Yu, N; Zhang, D; Zhao, D; Zhu, R; Zuo, J, 2017)
"We observed no effect of treatment on body weight gain, body condition score change, or wither height change."	( Erickson, MG; Gramer, S; Karcher, EL; Lock, AL; Preseault, CL; Tap, C; Trottier, N; VandeHaar, MJ; Worden, LC; Ylioja, C, 2018)
"Icariside II treatment improved body weight, heart/body weight ratio and fasting blood glucose in diabetic model rats."	( Cao, Y; Peng, C; Tian, L; Tian, Y; Xia, J; Yang, L; Yang, X; Zhang, W, 2018)
"Subjects were phenotyped pre- and post-treatment for body weight, adiposity by dual energy X-ray absorptiometry, energy expenditure by indirect calorimetry, food intake, oral glucose tolerance, plasma lipids, glucose, insulin, and other hormones."	( Ballon, JS; Contreras, I; Freyberg, R; Freyberg, Z; Leibel, RL; Lieberman, JA; Mayer, LE; Pajvani, UB; Rosenbaum, M, 2018)
"After POL extract treatment, body weights of rats significantly increased, macroscopic and microscopic damage scores reduced, MPO and NOS activity, as well as MDA and NO level significantly decreased, while SOD activity increased in a dose-dependent manner in the TNBS + POL groups compared with the TNBS group."	( Dong, L; Gao, JP; Huang, Y; Wang, Y; Yin, J; Zhao, JH, 2018)
"Adenine treatment reduced body weight, creatinine renal clearance, and increased water intake and urine output, as well as the plasma concentrations of urea and creatinine, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-D-glucosaminidase activity, and albumin in urine."	( Adham, SA; Al Kalbani, J; Al Suleimani, Y; Al Za'abi, M; Ali, BH; Karaca, T; Manoj, P; Nemmar, A; Yasin, J, 2018)
"In Ppara-null mice, MFD treatment increased body weight, adipose tissue, serum TG and impaired glucose tolerance."	( Dai, M; Gonzalez, FJ; Hua, H; Huang, J; Lin, H; Liu, A; Liu, L; Wang, F; Xi, Y; Xu, G; Yang, J; Zhao, T, 2018)
"Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice."	( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019)
"At the end of 3-week treatment, mean body weight was 28."	( Fu, L; Gu, CW; Han, JH; Wei, LW; Yuan, ZQ; Zhao, MD, 2018)
"Considering that oxytocin treatment decreases body weight in obese animals and humans, we investigated the effects of oxytocin and leptin cotreatment."	( Altirriba, J; Caillon, A; Chrétien, C; Labyb, M; Rohner-Jeanrenaud, F, 2018)
"Glycine treatment increased body weight gain, reduced blood glucose, and increased plasma insulin levels compared to diabetic control rats, and also increased GSH content and decreased mRNA and protein levels of aldose reductase compared to their respective controls."	( Li, W; Shao, N; Zhang, Y, 2019)
"During long-term treatment, mean body weight increased by 3."	( Eriksson, H; Meehan, SR; Newcomer, JW; Weiss, C; Zhang, P, 2019)
"After six months of treatment, the body weight and body fat percentage decreased significantly, while the body muscle percentage increased significantly."	( Hashimoto, N; Kawai, H; Ohara, T; Onishi, T; Sawada, T; Shimane, A; Takaya, T; Taniguchi, Y; Uzu, K; Yasaka, Y, 2020)
"During tramadol treatment a body weight loss followed by an increase, when treatment was terminated, was observed in all laboratories."	( Abdelrahman, A; Bleich, A; Durst, M; Häger, C; Jirkof, P; Keubler, L; Potschka, H; Struve, B; Talbot, SR; Vollmar, B; Zechner, D, 2020)
"Two weeks of coumestrol treatment reduced body weight and improved glucose tolerance of high-fat diet (HFD)-fed mice."	( Ahn, SY; Cho, YK; Jeong, HW; Jung, YS; Kim, SN; Kwon, HJ; Lee, YH; Saha, A; Son, Y; Song, HD, 2020)
"Amylin treatment improves body weight and glucose control, although it is limited by a short action and need for high doses."	( Andreassen, KV; Henriksen, K; Karsdal, MA; Larsen, AT; Sonne, N, 2020)
"Here, we show that in mice disulfiram treatment prevented body weight gain and abrogated the adverse impact of an obesogenic diet on insulin responsiveness while mitigating liver steatosis and pancreatic islet hypertrophy."	( Ali, A; Aon, MA; Becker, KG; Bernier, M; Cai, H; Cogger, VC; Cuervo, AM; de Cabo, R; Di Francesco, A; Di Germanio, C; Diaz, A; Egan, JM; Enamorado, IN; Fernandez-Hernando, C; Fishbein, K; Gao, B; Guiterrez, V; Harney, D; Kaiser, T; Kim, EY; Koay, YC; Lakatta, EG; Larance, M; LeCouteur, DG; Mach, J; Mitchell, SJ; O'Sullivan, J; Petr, MA; Price, NL; Pulpitel, T; Seo, W; Singh, A; Spencer, RG; Wahl, D; Wang, M; Wang, Y; Warren, A; Zhang, J; Zhang, L, 2020)
"However, patients who received MPH treatment had less body weight gain than the nonmedicated group."	( Chou, WJ; Huang, YH; Lee, SY; Wang, LJ, 2022)
"After 12 weeks of treatment, the body weight decreased significantly from 76."	( Jung, H; Kim, TH; Lee, WS; Lim, S; Sohn, M, 2023)
"After DMF treatment, the body weight of hypothyroid rats recovered, and the levels of T3 and T4 in the serum were ameliorated."	( Pan, H; Wang, X; Wang, Y; Yan, C, 2022)
"Intriguingly, morin treatment (20 mg/kg body weight) for 17 days effectively attenuated the loss of muscle mass and muscle protein and suppressed the expression of ubiquitin ligases while reducing the expression of upstream transcriptional factors."	( Fukawa, T; Hirasaka, K; Kanayama, HO; Maru, I; Mawatari, K; Nakao, R; Nikawa, T; Osaki, K; Rahman, MM; Sakakibara, I; Uchida, T; Ulla, A, 2022)
"Accordingly, the cost needed to treat per 1% of body weight reduction with tirzepatide is estimated at $985 (95% CI: $908-$1075) compared with $1845 (95% CI: $1707-$1989) with semaglutide."	( Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A; Sluckis, B, 2023)
"Accordingly, the cost needed to treat per 1% of body weight reduction with tirzepatide is estimated at $985 (95% CI: $908-$1075) compared with $1845 (95% CI: $1707-$1989) with semaglutide."	( Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A; Sluckis, B, 2023)
"After 8-weeks of treatment, body weight, daily water intake, fasting blood glucose levels were measured and eye tissue was harvested."	( Herat, LY; Matthews, JR; Matthews, VB; Rakoczy, EP; Schlaich, MP, 2023)
"Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032-$3517) compared with $1845 (95% CI: $1707-$1989) with semaglutide."	( Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A; Sluckis, B, 2023)
"During the 49-day treatment, body weight and blood glucose were measured weekly."	( Abtahi-Foroushani, M; Babaei-Balderlou, F; Goshadezehn, P; Najafi, GR; Razi, M, 2023)

Excerpt

Reference

"During the 7 weeks of treatment body weight increased 7 kgrams."

( Böhles, H; Fekl, W; Heid, H; Koch, H, 1977)

"After treatment, whole body weights and wet organ weights of liver, spleen, and kidney, as well as gross and histologic changes in these and other tissues, were monitored on Days 1, 4, 7, 11, 15, 21, and 28."

( Baker, WH; Jackson, WE; Nold, JB; Patchen, ML, 1992)

"Daily corticosterone treatment decreased body weight and food intake."

( Haleem, DJ, 1992)

"During reserpine treatment, body weight and food intake were significantly reduced from the 2nd day on."

( Benrezzak, O; Bérubé, FL; Morisset, J, 1991)

"Survival was not adversely affected by treatment, however, body weight of males and females in the high dose group was significantly lower than that of controls."

( Bendele, AM; Eacho, PI; Foxworthy, PS; Hoover, DM; van Lier, RB, 1990)

"Ethanol pretreatment and body weight had no effect on MEGX levels at any of the time points tested in this model."

( Druckenbrod, RW; Mendenhall, CL; Myre, SA; Schroeder, TJ; Stanberry, EA, 1991)

"Chronic fencamfamine treatment reduced body weight of rats below their normal body weight."

( Aizenstein, ML; DeLucia, R; Planeta, Cda S; Scavone, C, 1987)

"At the end of treatment, body weights were reduced in higher dose groups of sulfasalazine, CH 74A and sulfapyridine compared to control animals."

( Agback, H; Bardin, CW; Didolkar, AK; Johansson, ED; Keizer-Zucker, A; Sundaram, K, 1988)

"Findings suggest that DHEA acetate treatment affected body weight, body composition and utilization of dietary energy by both impairing fat synthesis and promoting fat-free tissue deposition and resting heat production."

( Davis, JR; Tagliaferro, AR; Truchon, S; Van Hamont, N, 1986)

"During three days' treatment, body weight in Group II increased significantly compared with that in Group I (P less than 0."

( Hamada, S; Imura, H; Nakamura, H; Nanno, M; Ohtsuka, R; Yoshimi, T, 1987)

"Bromocriptine treatment reduced body weight and decreased the plasma levels of prolactin, glucagon and insulin, as compared to non-treated tumor-bearing rats."

( Gautvik, K; Haug, E; Johansen, PW; Knudtzon, J, 1986)

"This treatment decreased body weights and increased significantly the relative weights of the hearts."

( Ali, BH; Czarnecki, CM, 1987)

"During the pretreatment period, body weight and plasma tryptophan levels were measured and the Beck Depression Inventory, SCL 90 rating, and Profile-of-Mood State (POMS) were used to assess mood."

( Strain, GW; Strain, JJ; Zumoff, B, 1985)

"Since post-treatment body weight changes correlated with daily food intakes (r = 0."

( Dubuc, PU, 1985)

"There was no effect of treatment on body weights through 12 mo of age."

( Garza, F; Jones, LS; Southern, LL; St George, RL; Thompson, DL, 1985)

"Gestational age, gender, duration of treatment, body weight, and Apgar scores were not found to correlate significantly with theophylline clearance."

( Erkan, NV; Gal, P; Gilman, JT; Hersh, CB; Levine, RS, 1986)

"In the long-term treatment group, body weight showed a slight mean decrease."

( Arberg-Wistedt, A; Jozwiak, H; Nyström, C; von Knorring, L; Wålinder, J, 1983)

"Nestlings and adults with low pretreatment body weights appeared to be more vulnerable to organophosphate (OP) exposure."

( Grue, CE; Shipley, BK, 1984)

"On the other hand, from days 5 to 14 of treatment, body weight and food intake increased, though they were still lower than in sham-operated controls."

( Faure, A; Sutter, BC; Sutter-Dub, MT; Vergnaud, MT, 1984)

"The effect of diazepam treatment on body weight was compared to that of vehicle treatment in the following groups: (1) young adult females, (2) pregnant females, (3) shock treated young males (4) nonshocked young males."

( Grimm, VE; Jancourt, A, 1983)

"In the second experiment, GBL-treated rats had body weights similar to those of control rats, but testicular weights were significantly decreased."

( Debeljuk, L; Díaz, MD; Maines, VM; Seilicovich, A, 1983)

"After 4 weeks of treatment, the body weight increase was similar in all treated groups."

( Broer, Y; Fouchereau-Peron, M; Rosselin, G, 1981)

"At the end of 7 and 14 days treatment period, body weight gain, serum protein, serum glucose, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) were measured."

( Boykin, M; Butts, A; Chapatwala, KD; Rajanna, B, 1982)

"At the end of the treatments, the body weight gains, serum glucose, serum protein, serum glutamic oxalacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) were determined."

( Chapatwala, KD; Desaiah, D; Rajanna, B, 1980)

"In 38 patients investigated before treatment body weight was normal while mean TBK was 91% of predicted in men and 100% in women."

( Attman, PO; Ewald, J; Isaksson, B, 1980)

"In the lean rats, (-)-hydroxycitrate treatment decreased body weight, food intake, percent of body fat, and fat cell size."

( Blase, D; Cleary, MP; Greenwood, MR; Gruen, R; Stern, JS; Sullivan, AC; Triscari, J, 1981)

"During 1 year of treatment body weight fell by 11."

( Blomberg, I; Luft, D; Pfohl, M; Schmülling, RM, 1994)

"In the duodenum, PGE2 treatment (4 mg/kg body weight) produced a significant increase in crypt depth (35%, p < 0."

( Fernandez-Otero, MP; Marti, A, 1994)

"During the luteal phase of the pretreatment cycle, body weight and blood pressure were recorded, and plasma levels of the following variables were recorded: sex-hormone-binding globulin (SHBG), cortisol-binding globulin (CBG), testosterone, free testosterone, dihydrotestosterone, androstenedione, dihydroepiandrosterone sulfate (DHEAS), and hydroxyprogesterone."

( Borm, GF; Coenen, CM; Rolland, R; Thomas, CM, 1995)

"In OVX rats treated with DRO, body weight decreased significantly in a dose-response manner, and total serum cholesterol was significantly reduced by 65% to 70% compared to both sham and OVX controls."

( Chen, HK; Jee, WS; Ke, HZ; Ma, YF; Pirie, CM; Qi, H; Simmons, HA; Thompson, DD, 1995)

"Non-transgenic control mice were treated similarly."

( Murray, JD; Oberbauer, AM; Pomp, D, 1996)

"At 72 hr after treatment, body weight gain was significantly decreased in the 100 mg/kg CIS group and in all CT dose groups."

( Elwell, MP; Jeter, SP; Morgan, DL; Moskowitz, PD; Price, HC; Shines, CJ; Wilson, RE, 1995)

"Aldosterone (type I agonist) treatment increased body weight gain and returned energy accretion to the level of sham-operated animals."

( Edwards, GL; Martin, RJ; White, BD, 1996)

"After stopping the treatment, the body weight and food consumption in the diazepam 100 and 300 mg/kg groups tended to decrease or decreased to values lower than those in the control group, whereas these parameters in the S-(+)-DN-2327 30, 100 and 300 mg/kg groups were comparable to the control group values."

( Awasaki, Y; Inui, Y; Nishida, N; Yamamoto, M, 1996)

"Post-treatment body weights were approximately 5% greater in the CL group compared to CON (P < 0."

( Criswell, DS; Herb, RA; Powers, SK, 1996)

"After a median of 176 days on treatment, body weight had increased in 119 out of the 160 patients followed (74."

( Aussel, C; Beaugerie, L; Carbonnel, F; Carrat, F; Cosnes, J; Gendre, JP; Girard, PM; Gobert, JG; Maslo, C; Rozenbaum, W; Wirbel, E, 1998)

"After 4-wk of treatment, the body weight of the ethanol group was 7% and of the pair-fed rats 19% lower than that of the absolute controls."

( Benický, J; Brtko, J; Nikodémová, M; Strbák, V, 1998)

"Following Aroclor 1254 treatment, body weight gain in the high-dose group was significantly lower than the control and low-dose groups."

( Barone, S; Choksi, NY; Derr-Yellin, EC; Herr, DW; Kodavanti, PR; MacPhail, RC; Mundy, WR; Shafer, TJ; Tilson, HA, 1998)

"There was no effect of oxytocin treatment on body weight or weight gain in either of the feeding groups."

( Bang, P; Brismar, K; Carlsson-Skwirut, C; Sohlström, A; Uvnäs-Moberg, K, 1999)

"At the termination of the treatment, the body weight of SAM P8 was markedly lower than that of the equal aged senescence-resistant prone 1 (SAM R1), but this was conspicuously recovered to the level of SAM R1 by SDT treatment."

( Joo, HJ; Jung, KY; Lee, MY; Ma, JY; Park, JH; Yang, JM, 1999)

"After treatment, body weight was approximately 10% greater in Ovx than in Sham rats (P < 0."

( Brown, M; Fisher, JS; Kohrt, WM, 2000)

"Within the Cd plus MLT-treated group, the body weight gains and relative thymus weights were significantly increased when compared with the treatment of Cd alone."

( Ahn, YK; Kim, JH; Kim, YO, 2000)

"Chronic exendin-4 treatment reduced body weight in both obese and lean Zucker rats by reducing food intake: metabolic rate was apparently suppressed."

( Al-Barazanji, KA; Arch, JR; Buckingham, RE; Tadayyon, M, 2000)

"Within the Pb plus MLT-treated group, the body weight gains and the relative thymus weights were significantly increased when compared with the treatment of Pb alone."

( Kim, JH; Kim, YO; Pyo, MY, 2000)

"Drug treatment affected body weight, glandular weight, DNA synthesis, and the concentration of soluble and structural membrane proteins."

( Cowman, RA; Humphreys-Beher, MG; Koller, MM; Scarpace, PJ, 2001)

"Six replicates were allotted to each treatment."

( Lefrançois, MR; Nahas, J, 2001)

"After treatment, body weight largely recovered to 90-95% of controls."

( Broening, HW; Fukumura, M; Inman-Wood, SL; Morford, LL; Vorhees, CV, 2001)

"Five days of lycopene pretreatment (10 mg/kg body weight, ip) almost completely prevented liver biomolecule oxidative damage and protected the tissue against the observed histological alterations."

( Capelozzi, VL; Gomes, OF; Mascio, PD; Matos, HR; Medeiros, MH, 2001)

"Before and after the 3-month treatment with CAM, body weight, serum levels of interleukin-6 (IL-6, a cytokine which, together with TNF-alpha, plays a crucial role in the development of cancer cachexia), total protein, albumin, cholinesterase and hemoglobin were measured for the evaluation of the patients' clinical status."

( Hamada, K; Kita, E; Konishi, M; Maeda, K; Majima, T; Mikasa, K; Narita, N; Sakamoto, M, 2001)

"Cows were blocked by pretreatment body weight and energy-corrected milk (ECM) and assigned to control, SHSL (20."

( DeFrain, JM; Ethington, RT; Park, AF; Shirley, JE; Titgemeyer, EC, 2002)

"There was no effect of any treatment on body weight; however, there was a significant reduction in both food and fluid intake in fatty groups treated with BEOV."

( Battell, ML; Bhanot, S; McNeill, JH; Orvig, C; Yuen, VG, 2003)

"Post-treatment body weights and skeletal muscle weights were not affected by clenbuterol treatment."

( Bigard, AX; Bricout, VA; Serrurier, BD, 2004)

"In STZ-treated rats body weight decreased and plasma glucose and glycosylated hemoglobin increased."

( Bergren, DR; Rendell, MS, 2004)

"Fenofibrate treatment decreased body weight gain and WAT mass in OVX, but not in Sham mice."

( Choi, JH; Han, M; Jeong, S; Kim, BH; Kim, J; Kim, M; Lee, H; Nam, KH; Nicol, CJ; Oh, GT; Yoon, M, 2004)

"Both groups of oleoyl-estrone-treated rats lost body weight, energy, and lipid; the losses in the rats receiving tamoxifen alone were less marked than in those receiving oleoyl-estrone."

( Alemany, M; Fernández-López, JA; Ferrer-Lorente, R; García-Peláez, B; Remesar, X, 2004)

"Up to 90 days daily oral crude neem oil treatment (5 g/kg body weight) of laboratory mice did not cause any significant changes in weekly body weight gain, nor in serum liver damage indicators, direct bilirubin or total bilirubin."

( Awad, OM, 2003)

"There was no effect of treatment on body weight at PN115."

( Mooney, SM; Napper, RM, 2005)

"Fluoxetine treatment reduced body weight within the first 24 h of treatment."

( Grossie, B; Hensler, JG; Sarkar, J; Uphouse, L, 2006)

"Following the treatment period, body weight gain was identical in the four groups."

( Berthelot, A; Figard, H; Gaume, V; Mougin, F, 2006)

"Insulin treatment reversed body weight loss and corrected hyperglycemia at diabetic rats as expected."

( Chen, M; Georgeson, KE; Harmon, CM; Loux, TJ; Yang, YK, 2006)

"After the treatment, lung/body weight ratio in the mutant strain was significantly larger than that in the wild-type mice."

( Akishita, M; Horiuchi, M; Oishi, Y; Oshima, T; Ozono, R; Yoshizumi, M, 2006)

"Birds on FWD treatment lost more body weight during the molting period, but gained more after molt compared to thyroxine treatments (P<0."

( Bass, PD; Hooge, DM; Koutsos, EA, 2007)

"Open-label sibutramine treatment decreased body weight 4."

( Diedrich, A; Engeli, S; Heusser, K; Janke, J; Jordan, J; Luft, FC; Tank, J; Wiesner, S, 2007)

"Following maprotiline treatment, the body weight and BMI were significantly increased (P=0."

( Chen, YC; Chou, CH; Hung, YJ; Perng, CH; Shen, YC; Yeh, CB, 2007)

"Metformin may safely assist olanzapine-treated patients in body weight and carbohydrate metabolism control."

( Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M, 2007)

"At 26, 39, or 52 weeks of treatment, body weight gain was significantly reduced by 7."

( Bagchi, D; Bagchi, M; Barrett, L; Bramble, JD; Chatterjee, A; Kincaid, AE; Limpach, AL; Norton, N; Sandstrom, R; Shara, M; Tran, J; Yasmin, T, 2007)

"Leptin treatment reduced body weight of both MHF diet- and chow-fed male mice but failed to prevent the decrease in Y(1)R/LacZ transgene expression apparent in the DMH and VMH of male mice after 8 weeks of MHF diet intake."

( Eva, C; Panzica, G; Zammaretti, F, 2007)

"However, many antidiabetic treatments increase body weight."

( Golay, A, 2008)

"Days in milk were similar between treatments, and body weight and milk yield were unaffected by treatment."

( Cobb, C; Hill, SR; Knowlton, KF; Taylor, MS; Wilson, KF, 2007)

"In conclusion, DHEA treatment decreases body weight and adiposity in old female rats fed a high-fat diet, leading to an improvement of the HOMA index for insulin sensitivity, with decreasing circulating insulin levels, and preventing the age-associated decline of visceral-adipose adiponectin expression."

( Garaulet, M; Palou, A; Pérez-Heredia, F; Portillo, MP; Priego, T; Sánchez, J; Zamora, S, 2008)

"After 3-week Rhodiola rosea treatment, the body weight and 1% sucrose intake increased in rats of the low-dose Rhodiola rosea group and recovered to the level of the normal control group."

( Chen, QG; Chen, SJ; Qin, YJ; Tang, JY; Zeng, YS; Zhong, ZQ, 2008)

"In PPSBPE treated mice the body weight was not reduced in contrast to that in vehicle group."

( Badole, SL; Bodhankar, SL, 2009)

"Captopril treatment decreased body weight in the first 2 weeks of treatment."

( Begg, DP; Jois, M; Spark, KJ; Stanley, TK; Weisinger, HS; Weisinger, RS, 2009)

"The effects of chronic rimonabant treatment on body weight gain occurred irrespective of diet-induced changes in lipogenic activity, food intake and daily energy expenditure, and were, in fact, most pronounced in HF/FO mice."

( Bloks, VW; Jonas, I; Koolman, AH; Kuipers, F; Oosterveer, MH; Sauer, PJ; van Dijk, G, 2010)

"After 20 treatments, the body weight, waistline, and the serum total cholesterol (TC), the fasting triglyceride (TG) and low-density lipoprotein (LDL) were significantly changed (P < 0."

( Wu, ZH, 2009)

"Dexamethasone treatment evoked body weight loss (-24%), followed by muscular atrophy in the tibialis anterior (-25%) and the extensor digitorum longus (EDL, -15%)."

( Barel, M; Bosqueiro, JR; do Amaral, SL; Giozzet, VA; Perez, OA; Rafacho, A, 2010)

"In contrast, insulin treatment increased body weight (1."

( Aronoff, S; Blevins, T; Chen, S; Han, J; Nicewarner, D; Oliveira, JH, 2010)

"Adult male Wistar rats were either pre-treated with 2 mg/g body weight (BW) of powdered P."

( Dolder, H; Leite, RP; Monteiro, JC; Predes, FS; Wada, RS, 2011)

"After 4 weeks of drug treatment, body weights were noted and random blood glucose and insulin was estimated for the antidiabetic effect."

( Arumugam, S; Davis, JA; Misra, CS; Ray, A; Roy, S; Shah, V; Sharma, S; Shirumalla, RK, 2011)

"The rats in reserpine treated group, body weight, concentrations of IFN-γ, IL-1 and TNF-α in serum, expression of TGF-β in small intestine, VIP in small intestine decreased (P<0."

( Guo, Y; Jia, H; Liu, Z; Lu, A; Xu, S; Zha, Q; Zhang, W; Zhao, N, 2011)

"Sitagliptin treatment reduced body weight without changes in overall body mass index or in the epididymal and retroperitoneal fat mass."

( Coben, J; Dobrian, AD; Galkina, EV; Leone, KA; Lindsay, JW; Ma, K; Ma, Q; Nadler, JL, 2011)

"In HMB-treated TB, body weight was not lost but significantly (p=0."

( Aversa, Z; Baccino, FM; Bonetto, A; Costelli, P; Lucia, S; Minero, VG; Muscaritoli, M; Penna, F; Rossi Fanelli, F, 2011)

"Exenatide or insulin glargine treatment decreased body weight by 6%."

( Bunck, MC; Cornér, A; Diamant, M; Eliasson, B; Heine, RJ; Shaginian, RM; Smith, U; Taskinen, MR; Yki-Järvinen, H, 2011)

"During treatment, body weight of each pregnant mouse was measured daily."

( Cho, NK; Kim, DH; Kim, JH; Lee, CH; Lee, CK; Lee, JT; Son, BC; Suh, CH, 2011)

"Exenatide treatment reduced body weight and body mass index (BMI) and improved HbA1c, the seven-point glucose profile, and daily mean glucose compared with placebo (P < 0."

( Ding, B; Du, TX; Gao, G; Lee, KO; Ma, JH; Mao, XM; Wu, JD; Xu, XH; Ye, L; Zhu, J, 2011)

"After the eight-week treatment, body weight and body mass index showed to be significantly increased compared to those at baseline."

( Chen, CH; Chen, TT; Chen, VC; Lin, NC; Lin, TY; Lu, ML; Shao, WC, 2011)

"Compared with pre-treatment, the body weight and BMI and serum leptin levels in the control and treatment groups were all decreased significantly (P < 0."

( Li, M; Li, Q; Wang, SJ; Xiao, HL; Xing, HJ; Yang, JJ, 2010)

"The I3C treatment decreased body weight and fat accumulation and infiltrated macrophages in epididymal adipose tissue of DIO mice, and these reductions were associated with improved glucose tolerance and with modulated expression of adipokines and lipogenic-associated gene products, including acetyl coenzyme A carboxylase and peroxisome proliferator-activated receptor-γ."

( Chan, MH; Chang, HP; Chen, YH; Chiu, YS; Wang, ML, 2011)

"After 14 weeks of treatment, body weight, abdominal fat, blood lipid and serum insulin level were measured, and the protein and gene expression of PTP1B in liver tissue was tested."

( Chang, B; Li, M; Liu, WK; Qin, PJ; Tong, XL; Zhen, Z, 2011)

"These results indicate that GSK232802A treatment reduces body weight and adiposity in ovariectomized nonhuman primates by suppressing food intake and increasing activity, particularly in the most sedentary individuals."

( Cameron, JL; Koegler, FH; Shearin, J; Sullivan, EL, 2012)

"Exendin-4 treatment decreased body weight, serum free fatty acid (FA), and triglyceride levels in HF-induced obese C57BL/6J mice."

( Bae, JC; Chae, SW; Choi, JH; Hong, SW; Kim, DH; Kim, SW; Lee, J; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ, 2012)

"In GK rats, 23 days of treatment increased body weight but did not cause hemodilution."

( Gao, W; Jusko, WJ, 2012)

"After the treatment period, body weight decreased (-2."

( Dohi, K; Hoshino, K; Ichikawa, K; Ito, M; Kumagai, N; Machida, H; Nakajima, H; Nakamori, S; Nakamura, M; Nobori, T; Okamoto, S; Onishi, K; Sato, Y; Sugimoto, T; Sugiura, E; Watanabe, K; Yamada, T, 2012)

"In testosterone- and vehicle-treated rats, body weights and food intake did not differ."

( Armstrong, A; Fridkin, V; Jakowec, M; Najafi, A; Shah, V; Wood, RI, 2013)

"In obese mice, after 8-week treatment, the body weight gain was significantly more suppressed by both 1 mg/kg and 2 mg/kg of DA-3091, monthly subcutaneous administered, than by 10 mg/kg/day of sibutramin, a drug against obesity."

( Jun, SW; Kang, JS; Kang, SH; Kwak, HH; Park, YI; Son, JP; Son, MK, 2013)

"The results indicated that neonatal PCP treatment reduced body weight during neonatal and adulthood periods, and did not alter baseline corticosterone levels in both male and female mice."

( Amani, M; Azarfarin, M; Bakhtiari, A; Doosti, MH; Majidi-Zolbanin, N; Mirza-Rahimi, M; Salari, AA; Samadi, H, 2013)

"Corticosterone treatment increased body weight and food intake for the duration of the treatment and increased gonadal and subcutaneous white adipose tissue weight in transient group by +35% and +31%, and in the continuous group by +140% and 110%."

( Auvinen, HE; Biermasz, NR; Havekes, LM; Meijer, OC; Pereira, AM; Princen, H; Rensen, PC; Romijn, JA; Smit, JW; Wang, Y, 2013)

"The results showed that oxymatrine treatment reduced body weight gain, liver weight, liver index, dyslipidemia, and liver triglyceride level in a dose dependant manner."

( Hu, ZJ; Shi, L; Shi, LJ; Song, GY; Wang, C; Zhang, DH; Zhang, HF, 2013)

"In vivo, T3 and T2 treatment induced body weight gain in tilapia."

( Luna, M; Navarrete-Ramírez, P; Orozco, A; Valverde-R, C, 2014)

"After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups."

( Fan, H; Pan, Q; Xu, Y; Yang, X, 2013)

"Our results show that dexamethasone treatment reduced body weight and hippocampal volume transiently during development, but these effects were no longer detected at adulthood."

( de Graan, PN; de Vries, WB; Derks, JB; Hessel, EV; Noorlander, CW; Tijsseling, D; Visser, GH, 2014)

"However, there was no treatment effect on body weight (CON -2."

( Askew, EW; Drummond, MJ; Gershenoff, DC; Wing-Gaia, SL, 2014)

"After 8-week treatment, body weight, wet weight of visceral fat and the percentage of body fat (PBF) were measured."

( Chang, X; Chao, J; Han, S; Huang, Q; Lin, H; Lu, K; Qu, S; Shen, C; Song, X; Tan, M; Wang, C; Xie, S; Xu, L; Yuan, Q; Zhang, J, 2014)

"Preoperative treatment impaired body weight during the gavage period, but was without effect on liver regeneration."

( Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR, 2014)

"During treatment, maternal body weight gain, and food and water intake were evaluated."

( Bernardi, MM; Reis-Silva, TM; Sandini, TM; Spinosa, Hde S; Udo, MS, 2014)

"Dosage, length of treatment, age and body weight of the dogs were recorded as well as any adverse events that occurred during treatment."

( Cook, C; Schmeitzel, L; Short, J; Zabel, S, 2014)

"They were blocked based on pre-treatment body weight (range 22."

( Kellermann, M; Rehbein, S; Wehner, TA, 2014)

"Compared with before treatment, body weight, BMI, waist circumstance, and waist-hip ratio obviously decreased after treatment, showing significant difference when compared with the control group (P < 0."

( Liu, J; Meng, X; Xia, SY; Yu, H; Zhang, P; Zhang, YR, 2014)

"ACE 2 activation treatment lowered body weight (DIZE vs control) (28."

( Andrade, JM; Batista de Paula, AM; de Macedo, SM; Ferreira, AJ; Guimaraes, AL; Guimarares, TA; Sousa Santos, SH, 2015)

"Exendin-4 treatment deceased body weight, serum-free fatty acid, and triglyceride levels in HFD-induced obese C57BL/6J mice."

( Chen, JA; Li, L; Sun, ZL; Wang, SH; Wei, Q, 2015)

"Compared before the treatment, SBP, WC, body weight, BMI, FPG, OG-TT2hBG, FINS, GTT2h insulin, HOMA-IR, TC and LDL-C in the acupuncture group were all significantly reduced (all P <0."

( Liu, Y; Yang, Y, 2015)

"After 12 weeks of treatment ETP, body weight and food intake were analyzed."

( Ainödhofer, H; Cvirn, G; Gruber, HJ; Haybaeck, J; Kieslinger, P; Mangge, H; Obermayer-Pietsch, B; Pailer, S; Prüller, F; Zelzer, S, 2015)

"After two weeks of treatment, body weight, food intake,fasting glucose, impaired glucose tolerance, and other indicators were measured."

( Ding, CY; Shi, NC; Tan, QY, 2015)

"After 8 weeks of treatment, body weight, adipose tissue and liver mass were measured, and liver and plasma lipid levels were determined to evaluate to effect of FSE with or without AS treatment on diet-induced obesity, hyperlipidemia and hepatic steatosis."

( Cheung, DW; Fung, KP; Koon, CM; Lau, CB; Lau, CP; Leung, PC; Ng, CF; Wat, E; Wong, EC, 2016)

"Liraglutide as adjunct to insulin treatment reduced body weight and daily dose of insulin compared with insulin alone."

( Dejgaard, TF; Frandsen, CS; Holst, JJ; Madsbad, S, 2016)

"This treatment increased body weight gain and reduced feed conversion ratio, leading to superior growth performance."

( Chang, CL; Muthamilselvan, T; Yang, CY; Yang, WC, 2016)

"Results showed that (-)-HCA treatment reduced body weight gain and increased feed conversion ratio in rats."

( Han, N; Li, L; Ma, H; Peng, M, 2016)

"After 12 weeks of treatment, body weight, uterine index and the dry weight of thigh‑bones were recorded."

( Huang, KB; Qin, RZ; Yang, XW; Yang, YX; Zhou, QL, 2016)

"Luteolin treatment (15mg/kg body weight, p."

( Barua, CC; Bodduluru, LN; Gogoi, R; Kasala, ER, 2016)

"After the last treatment course, body weight, energy intake, serum lipopolysaccharides (LPS), insulin resistance, and fecal short-chain fatty acids (SCFAs) were compared."

( Gao, Z; Hu, H; Li, X; Liu, G; Mei, X; Wang, Z; Zhang, X; Zou, L, 2016)

"After OTA treatment, the body weight decreased and AST, ALP, TP, and BUN levels in serum increased."

( Gao, J; He, X; Huang, K; Luo, H; Qi, X; Xu, W; Yu, T; Zhu, L, 2016)

"All patients completed the treatment."

( Guo, M; Li, Y; Lu, C, 2016)

"Chronic adiponectin treatment reduced body weight, total cholesterol, free fatty acids, fasting glucose and area under the curve of intraperitoneal glucose tolerance test, compared with HFD rats."

( Fernandes, R; Letra, L; Pereira, A; Seiça, RM; Sena, CM, 2017)

"Before and after drug treatment, body weight was measured and blood was collected for assessment of lipid and liver function profiles."

( Annamalai, S; Dev, A; Mohanam, L; Prabhu, V; Raja, V, 2017)

"The results revealed that CA treatment decreased body weight, fat mass, food intake, and serum lipid, free fatty acid and leptin levels."

( Fang, X; Gao, S; Liu, H; Ma, R; Ma, Y; Mo, F; Mu, Q; Wang, L; Wu, R; Yu, N; Zhang, D; Zhao, D; Zhu, R; Zuo, J, 2017)

"We observed no effect of treatment on body weight gain, body condition score change, or wither height change."

( Erickson, MG; Gramer, S; Karcher, EL; Lock, AL; Preseault, CL; Tap, C; Trottier, N; VandeHaar, MJ; Worden, LC; Ylioja, C, 2018)

"Icariside II treatment improved body weight, heart/body weight ratio and fasting blood glucose in diabetic model rats."

( Cao, Y; Peng, C; Tian, L; Tian, Y; Xia, J; Yang, L; Yang, X; Zhang, W, 2018)

"Subjects were phenotyped pre- and post-treatment for body weight, adiposity by dual energy X-ray absorptiometry, energy expenditure by indirect calorimetry, food intake, oral glucose tolerance, plasma lipids, glucose, insulin, and other hormones."

( Ballon, JS; Contreras, I; Freyberg, R; Freyberg, Z; Leibel, RL; Lieberman, JA; Mayer, LE; Pajvani, UB; Rosenbaum, M, 2018)

"After POL extract treatment, body weights of rats significantly increased, macroscopic and microscopic damage scores reduced, MPO and NOS activity, as well as MDA and NO level significantly decreased, while SOD activity increased in a dose-dependent manner in the TNBS + POL groups compared with the TNBS group."

( Dong, L; Gao, JP; Huang, Y; Wang, Y; Yin, J; Zhao, JH, 2018)

"Adenine treatment reduced body weight, creatinine renal clearance, and increased water intake and urine output, as well as the plasma concentrations of urea and creatinine, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-D-glucosaminidase activity, and albumin in urine."

( Adham, SA; Al Kalbani, J; Al Suleimani, Y; Al Za'abi, M; Ali, BH; Karaca, T; Manoj, P; Nemmar, A; Yasin, J, 2018)

"In Ppara-null mice, MFD treatment increased body weight, adipose tissue, serum TG and impaired glucose tolerance."

( Dai, M; Gonzalez, FJ; Hua, H; Huang, J; Lin, H; Liu, A; Liu, L; Wang, F; Xi, Y; Xu, G; Yang, J; Zhao, T, 2018)

"Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice."

( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019)

"At the end of 3-week treatment, mean body weight was 28."

( Fu, L; Gu, CW; Han, JH; Wei, LW; Yuan, ZQ; Zhao, MD, 2018)

"Considering that oxytocin treatment decreases body weight in obese animals and humans, we investigated the effects of oxytocin and leptin cotreatment."

( Altirriba, J; Caillon, A; Chrétien, C; Labyb, M; Rohner-Jeanrenaud, F, 2018)

"Glycine treatment increased body weight gain, reduced blood glucose, and increased plasma insulin levels compared to diabetic control rats, and also increased GSH content and decreased mRNA and protein levels of aldose reductase compared to their respective controls."

( Li, W; Shao, N; Zhang, Y, 2019)

"During long-term treatment, mean body weight increased by 3."

( Eriksson, H; Meehan, SR; Newcomer, JW; Weiss, C; Zhang, P, 2019)

"After six months of treatment, the body weight and body fat percentage decreased significantly, while the body muscle percentage increased significantly."

( Hashimoto, N; Kawai, H; Ohara, T; Onishi, T; Sawada, T; Shimane, A; Takaya, T; Taniguchi, Y; Uzu, K; Yasaka, Y, 2020)

"During tramadol treatment a body weight loss followed by an increase, when treatment was terminated, was observed in all laboratories."

( Abdelrahman, A; Bleich, A; Durst, M; Häger, C; Jirkof, P; Keubler, L; Potschka, H; Struve, B; Talbot, SR; Vollmar, B; Zechner, D, 2020)

"Two weeks of coumestrol treatment reduced body weight and improved glucose tolerance of high-fat diet (HFD)-fed mice."

( Ahn, SY; Cho, YK; Jeong, HW; Jung, YS; Kim, SN; Kwon, HJ; Lee, YH; Saha, A; Son, Y; Song, HD, 2020)

"Amylin treatment improves body weight and glucose control, although it is limited by a short action and need for high doses."

( Andreassen, KV; Henriksen, K; Karsdal, MA; Larsen, AT; Sonne, N, 2020)

"Here, we show that in mice disulfiram treatment prevented body weight gain and abrogated the adverse impact of an obesogenic diet on insulin responsiveness while mitigating liver steatosis and pancreatic islet hypertrophy."

( Ali, A; Aon, MA; Becker, KG; Bernier, M; Cai, H; Cogger, VC; Cuervo, AM; de Cabo, R; Di Francesco, A; Di Germanio, C; Diaz, A; Egan, JM; Enamorado, IN; Fernandez-Hernando, C; Fishbein, K; Gao, B; Guiterrez, V; Harney, D; Kaiser, T; Kim, EY; Koay, YC; Lakatta, EG; Larance, M; LeCouteur, DG; Mach, J; Mitchell, SJ; O'Sullivan, J; Petr, MA; Price, NL; Pulpitel, T; Seo, W; Singh, A; Spencer, RG; Wahl, D; Wang, M; Wang, Y; Warren, A; Zhang, J; Zhang, L, 2020)

"However, patients who received MPH treatment had less body weight gain than the nonmedicated group."

( Chou, WJ; Huang, YH; Lee, SY; Wang, LJ, 2022)

"After 12 weeks of treatment, the body weight decreased significantly from 76."

( Jung, H; Kim, TH; Lee, WS; Lim, S; Sohn, M, 2023)

"After DMF treatment, the body weight of hypothyroid rats recovered, and the levels of T3 and T4 in the serum were ameliorated."

( Pan, H; Wang, X; Wang, Y; Yan, C, 2022)

"Intriguingly, morin treatment (20 mg/kg body weight) for 17 days effectively attenuated the loss of muscle mass and muscle protein and suppressed the expression of ubiquitin ligases while reducing the expression of upstream transcriptional factors."

( Fukawa, T; Hirasaka, K; Kanayama, HO; Maru, I; Mawatari, K; Nakao, R; Nikawa, T; Osaki, K; Rahman, MM; Sakakibara, I; Uchida, T; Ulla, A, 2022)

"Accordingly, the cost needed to treat per 1% of body weight reduction with tirzepatide is estimated at $985 (95% CI: $908-$1075) compared with $1845 (95% CI: $1707-$1989) with semaglutide."

( Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A; Sluckis, B, 2023)

"Accordingly, the cost needed to treat per 1% of body weight reduction with tirzepatide is estimated at $985 (95% CI: $908-$1075) compared with $1845 (95% CI: $1707-$1989) with semaglutide."

( Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A; Sluckis, B, 2023)

"After 8-weeks of treatment, body weight, daily water intake, fasting blood glucose levels were measured and eye tissue was harvested."

( Herat, LY; Matthews, JR; Matthews, VB; Rakoczy, EP; Schlaich, MP, 2023)

"Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032-$3517) compared with $1845 (95% CI: $1707-$1989) with semaglutide."

Timeframe	Studies, This Condition (%)	All Conditions %
pre-1990	38791 (39.37)	23.3326
1990's	16133 (16.37)	12.5806
2000's	20168 (20.47)	18.1394
2010's	19521 (19.81)	28.8240
2020's	3918 (3.98)	9.53

Drug	Relationship Strength	Studies	Trials
acetylcarnitine	low	17	0
dinitrochlorobenzene	medium	13	1
ethylene dichloride	low	8	0
2,3-dihydroxybenzoic acid	low	1	0
chloroacetaldehyde	low	1	0
ethylene chlorohydrin	low	6	0
alpha-hydroxyglutarate	low	1	0
2-oxo-3-methylvalerate	low	4	0
alpha-ketoisovalerate	low	2	0
2,3-diphosphoglycerate	low	14	0
2,5-dichlorophenol	low	2	0
2-keto-4-methylvalerate	medium	23	5
protocatechuic acid	low	11	0
3-hydroxyanthranilic acid	low	1	0
3-hydroxykynurenine	low	1	0
dihydro-3-coumaric acid	low	1	0
acetoacetic acid	low	12	0
phosphoserine	low	16	0
gamma-aminobutyric acid	medium	194	2
4-hydroxybenzaldehyde	low	1	0
4-hydroxyphenylacetic acid	low	1	0
4-hydroxybenzoic acid	low	1	0
aminolevulinic acid	low	28	0
5-hydroxytryptophan	medium	54	1
ethylene glycol	low	23	0
acetic acid	medium	85	5
acetaldehyde	medium	50	1
acetamide	low	1	0
acetone	medium	66	2
adenine	medium	89	8
adipic acid	low	1	0
agmatine	low	12	0
allantoin	medium	21	1
curdlan	low	1	0
ammonium hydroxide	medium	369	23
anthranilic acid	low	1	0
arsenic acid	low	2	0
quinacrine	low	11	0
beta-alanine	medium	15	2
benzaldehyde	low	1	0

Synonyms(1)

Research Excerpts

Overview

Context

Actions

Treatment

Research

Studies (98,531)

Drugs Studied (8,079)

Protein Targets (5,888)